Basic Information

Faculty

• Faculty of Medicine

Email Address

• Email Address

  masuda.norikazu.4ckyoto-u.ac.jp

Academic Degree

• 23 Mar. 2001

  大阪大学博士（医学）

Academic Resume (Graduate Schools)

• 大阪大学, 大学院医学系研究科医学専攻博士課程, 修了

Academic Resume (Undergraduate School/Majors)

• 大阪大学, 医学部, 卒業

Research History

• From May 2003, To Sep. 2021

  国立病院機構大阪医療センター, 外科・乳腺外科
• From Apr. 2024, To Present

  Kyoto University, Department of Breast Surgery, Graduate School of Medicine, Professor, MD, PhD
• From Oct. 2021, To Present

  名古屋大学大学院医学系研究科, 乳腺内分泌外科学, 教授

ID,URL

• ORCID ID

  0000-0002-7302-0278

• J-Global ID

  202301007895729780

• Researcher number

  50443536

researchmap URL

• https://researchmap.jp/norikazumasuda

Research

Research Interests

• Breast Cancer
• Clinical Trial

Papers

• Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers

  Jing Li; Ravi Velaga; Yuko Takano; Norikazu Masuda

  International Journal of Clinical Oncology, Dec. 2025

  
• Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer

  Sayumi Imamura; Kiyoshi Mori; Hiroyuki Yasojima; Makiko Mizutani; Kumiko Okada; Chie Hayashi; Masayuki Mano; Norikazu Masuda

  BMC Cancer, 04 Nov. 2025

  
• Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

  Masahiro Takada; Shigehira Saji; Takayuki Ueno; Norikazu Masuda; Hiroshi Ishiguro; Takanori Ishida; Toshiaki Saeki; Shigeru Imoto; Shinji Ohno; Hiroji Iwata; Tomoharu Sugie; Kenjiro Aogi; Shin Takayama; Nobuaki Sato; Yuichiro Kai; Masahiro Kitada; Rikiya Nakamura; Kenichi Watanabe; Yutaka Matsuyama; Masakazu Toi

  npj Breast Cancer, 24 Oct. 2025

  
• Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2

  Patrick Neven; Masakazu Toi; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Meena Okera; Norikazu Masuda; Peter A. Kaufman; Han Koh; Eva-Maria Grischke; Valentina Guarneri; Valérie André; Ashwin Shahir; Gertjan van Hal; George W. Sledge, Jr; Antonio Llombart-Cussac

  JCO Oncology Advances, Aug. 2025

  
• Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).

  Hiroko Bando; Aya Ueda; Kaori Terata; Mihoko Doi; Shigenori E Nagai; Masaya Hattori; Kenichi Watanabe; Nobuko Tamura; Manabu Futamura; Kei Koizumi; Naoki Niikura; Tempei Miyaji; Yasuaki Muramatsu; Linghua Xu; Norikazu Masuda; Shigehira Saji

  Breast cancer (Tokyo, Japan), 18 Jul. 2025

  
• Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

  Shigenori E Nagai; Masaya Hattori; Tetsuhiro Yoshinami; Hiroko Masuda; Takuho Okamura; Kenichi Watanabe; Takahiro Nakayama; Michiko Tsuneizumi; Daisuke Takabatake; Michiko Harao; Hiroshi Yoshino; Natsuko Mori; Hiroyuki Yasojima; Chiya Oshiro; Madoka Iwase; Miki Yamaguchi; Takafumi Sangai; Shinsuke Sasada; Takanori Ishida; Manabu Futamura; Yasuaki Muramatsu; Nobuyoshi Kosaka; Norikazu Masuda

  Breast cancer (Tokyo, Japan), Jul. 2025

  
• ATPase copper transporting beta attenuates malignant features with high expression as an indicator of favorable prognosis in breast cancer.

  Ikumi Soeda; Masahiro Shibata; Takahiro Inaishi; Takahiro Ichikawa; Kayoko Sugino; Emi Kanaya; Mitsuro Kanda; Masamichi Hayashi; Norikazu Masuda

  Breast cancer (Tokyo, Japan), Jul. 2025

  
• Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

  Tetsuhiro Yoshinami; Yuko Takano; Yukinori Ozaki; Yukiko Kajiwara; Mitsugu Yamamoto; Ken-Ichi Watanabe; Masami Tsukabe; Fumie Fujisawa; Shigenori E Nagai; Nobuhiro Shibata; Chiya Oshiro; Hiroko Bando; Nobuyuki Tsunoda; Kazuhiko Yamagami; Kei Koizumi; Masahiro Takada; Naoko Toriguchi; Nobuyuki Sekine; Tsutomu Kawaguchi; Shigehira Saji; Yasuaki Sagara; Satoshi Morita; Norikazu Masuda

  Breast cancer (Tokyo, Japan), Jul. 2025

  
• Precision Oncology Framework Using Circulating Tumor Cells.

  Fumihiko Kakizaki; Kyoichi Oshiro; Yuya Enoki; Kana Kawanishi; Norikazu Masuda; Hisatsugu Maekawa; Jun Matsubayashi; Masahiro Kawashima; Hiroyuki Miyoshi; Yukitoshi Takemura; Kazutaka Obama

  International journal of molecular sciences, 10 Jun. 2025

  
• Dynamic predictive power of TP53 signatures in breast cancer prognosis: Pre- and post-neoadjuvant chemotherapy insights.

  Keiju Sasaki; Shin Takahashi; Kota Ouchi; Hidekazu Shirota; Nobuaki Sato; Kouji Kaneko; Norikazu Masuda; Fumiyoshi Fujishima; Satoko Sato; Chikashi Ishioka

  Translational oncology, Jun. 2025

  
• Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.

  Shigeru Imoto; Hiroyuki Yasojima; Takeshi Nagashima; Tatsuya Onishi; Tsutomu Takashima; Masahiro Kitada; Masaya Kawada; Tetsu Hayashida; Yasuto Naoi; Tomohiko Aihara; Noriaki Wada; Hidetaka Kawabata; Masayuki Yoshida; Uhi Toh; Kimiyasu Yoneyama; Akimitsu Yamada; Hitoshi Tsuda; Norikazu Masuda; Mari Saito-Oba; Junichi Sakamoto

  Breast cancer (Tokyo, Japan), 25 May 2025

  
• Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

  Yumiko Akita; Ravi Velaga; Madoka Iwase; Satoko Shimada; Toyone Kikumori; Dai Takeuchi; Yuko Takano; Takahiro Ichikawa; Tomoki Ebata; Norikazu Masuda

  Breast cancer (Tokyo, Japan), 18 May 2025

  
• Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

  Yutaka Yamamoto; Hiroji Iwata; Shigehira Saji; Masato Takahashi; Tetsuhiro Yoshinami; Takayuki Ueno; Tatsuya Toyama; Takashi Yamanaka; Toshimi Takano; Masahiro Kashiwaba; Koichiro Tsugawa; Yoshie Hasegawa; Kenji Tamura; Hiroshi Tada; Fumikata Hara; Tomomi Fujisawa; Naoki Niikura; Naruto Taira; Satoshi Morita; Masakazu Toi; Shinji Ohno; Norikazu Masuda

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 May 2025

  
• Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

  Toshinari Yamashita; Shigehira Saji; Toshimi Takano; Yoichi Naito; Michiko Tsuneizumi; Akiyo Yoshimura; Masato Takahashi; Junji Tsurutani; Tsuguo Iwatani; Masahiro Kitada; Hiroshi Tada; Natsuko Mori; Toru Higuchi; Tsutomu Iwasa; Kazuhiro Araki; Kei Koizumi; Hiroki Hasegawa; Yohei Uchida; Satoshi Morita; Norikazu Masuda

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 Apr. 2025

  
• Institutional Variability in Ultrafast Breast MR Imaging: Comparing Compressed Sensing and View Sharing Techniques with Different Patient Populations and Contrast Injection Protocols.

  Maya Honda; Masako Kataoka; Mami Iima; Rie Ota; Aika Okazawa; Yasuhiro Fukushima; Marcel Dominik Nickel; Fumiaki Sato; Norikazu Masuda; Tsutomu Okada; Yuji Nakamoto

  Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 08 Feb. 2025

  
• Identification of peripheral blood test parameters predicting the response to palbociclib and endocrine therapy for metastatic breast cancer: a retrospective study in a single institution.

  Misato Yamamoto; Masahiro Shibata; Aya Tanaka; Nobuyuki Tsunoda; Norikazu Masuda

  Surgery today, Feb. 2025

  
• Impact of periodic neck ultrasonography on locoregional disease control in surveillance after total thyroidectomy for patients with low- and intermediate-risk papillary thyroid carcinoma: a propensity score-matched study.

  Takahiro Inaishi; Dai Takeuchi; Takahiro Ichikawa; Gai Inaguma; Atsushi Hashizume; Masaki Okazaki; Norikazu Masuda; Toyone Kikumori

  Endocrine journal, 02 Dec. 2024

  
• Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.

  Tomomi Nishimura; Ravi Velaga; Norikazu Masuda; Kosuke Kawaguchi; Shuji Kawaguchi; Masahiro Takada; Yurina Maeshima; Sunao Tanaka; Yuichiro Kikawa; Takayuki Kadoya; Hiroko Bando; Rikiya Nakamura; Yutaka Yamamoto; Takayuki Ueno; Hiroyuki Yasojima; Hiroshi Ishiguro; Satoshi Morita; Shinji Ohno; Hironori Haga; Fumihiko Matsuda; Seishi Ogawa; Masakazu Toi

  Cancer science, Dec. 2024

  Access this paper :

  
• Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).

  Takayuki Iwamoto; Naoki Niikura; Kenichi Watanabe; Takashi Takeshita; Yuichiro Kikawa; Kokoro Kobayashi; Nobutaka Iwakuma; Takuho Okamura; Takayuki Kobayashi; Yuriko Katagiri; Masahiro Kitada; Nobumoto Tomioka; Yasuo Miyoshi; Hideo Shigematsu; Minoru Miyashita; Hiroshi Ishiguro; Norikazu Masuda; Shigehira Saji

  Breast cancer research and treatment, Nov. 2024

  
• Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.

  Tadahiko Shien; Hitoshi Tsuda; Keita Sasaki; Junki Mizusawa; Futoshi Akiyama; Masafumi Kurosumi; Masataka Sawaki; Nobuko Tamura; Kiyo Tanaka; Takahiro Kogawa; Mina Takahashi; Naoki Hayashi; Hirofumi Mukai; Norikazu Masuda; Fumikata Hara; Hiroji Iwata

  Breast cancer research and treatment, Nov. 2024

  
• Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.

  Yoichi Naito; Seigo Nakamura; Nobuko Kawaguchi-Sakita; Takanori Ishida; Takahiro Nakayama; Yutaka Yamamoto; Norikazu Masuda; Koji Matsumoto; Takahiro Kogawa; Kazuki Sudo; Akihiko Shimomura; Catherine Lai; Danjie Zhang; Yuki Iwahori; Dianna Gary; Danh Huynh; Hiroji Iwata

  International journal of clinical oncology, Nov. 2024

  
• Adenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis.

  Kayoko Sugino; Masahiro Shibata; Yayoi Adachi; Ikumi Soeda; Takahiro Ichikawa; Takahiro Inaishi; Emi Kanaya; Mitsuro Kanda; Masamichi Hayashi; Norikazu Masuda

  Nagoya journal of medical science, Nov. 2024

  
• TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.

  Shin Takahashi; Nobuaki Sato; Kouji Kaneko; Norikazu Masuda; Masaaki Kawai; Hisashi Hirakawa; Tadashi Nomizu; Hiroji Iwata; Ai Ueda; Takashi Ishikawa; Hiroko Bando; Yuka Inoue; Takayuki Ueno; Shinji Ohno; Makoto Kubo; Hideko Yamauchi; Masahiro Okamoto; Eriko Tokunaga; Shunji Kamigaki; Kenjiro Aogi; Hideaki Komatsu; Masahiro Kitada; Yasuaki Uemoto; Tatsuya Toyama; Yutaka Yamamoto; Toshinari Yamashita; Takehiro Yanagawa; Hiroko Yamashita; Yoshiaki Matsumoto; Masakazu Toi; Minoru Miyashita; Takanori Ishida; Fumiyoshi Fujishima; Satoko Sato; Takuhiro Yamaguchi; Fumiaki Takahashi; Chikashi Ishioka

  Translational oncology, Oct. 2024

  
• Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.

  Seock-Ah Im; Javier Cortes; David W Cescon; Mastura Md Yusof; Hiroji Iwata; Norikazu Masuda; Toshimi Takano; Chiun-Sheng Huang; Chi-Feng Chung; Koichiro Tsugawa; Yeon Hee Park; Koji Matsumoto; Kenichi Inoue; Ava Kwong; Sherene Loi; Wei Fu; Wilbur Pan; Vassiliki Karantza; Hope S Rugo; Peter Schmid

  NPJ breast cancer, 12 Sep. 2024

  
• Clinical Experience with Simultaneous Mixed Infusion of Trastuzumab and Pertuzumab in the Neo-Peaks Study (JBCRG-20 Sub-Study).

  Hiroko Bando; Hiroyuki Yasojima; Kazushige Ishida; Kokoro Kobayashi; Hiroi Kasai; Masahiro Kashiwaba; Shinji Ohno; Satoshi Morita; Masakazu Toi; Norikazu Masuda

  Gan to kagaku ryoho. Cancer & chemotherapy, Sep. 2024

  
• A Century of Change: Unraveling the Impact of Socioeconomic/Historical Milestones on Age at Menarche and Other Female Reproductive Factors in Japan.

  Madoka Iwase; Yukari Taniyama; Yuriko N Koyanagi; Yumiko Kasugai; Isao Oze; Norikazu Masuda; Hidemi Ito; Keitaro Matsuo

  Journal of epidemiology, 05 Aug. 2024

  
• Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).

  Toshimi Takano; Norikazu Masuda; Mitsuya Ito; Kenichi Inoue; Yuko Tanabe; Kousuke Kawaguchi; Hiroyuki Yasojima; Hiroko Bando; Rikiya Nakamura; Takashi Yamanaka; Kazushige Ishida; Tomoyuki Aruga; Yasuhiro Yanagita; Eriko Tokunaga; Kenjiro Aogi; Shinji Ohno; Hiroi Kasai; Tatsuki R Kataoka; Satoshi Morita; Masakazu Toi

  Breast cancer research and treatment, Aug. 2024

  
• Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.

  Tetsuhiro Yoshinami; Shigenori E Nagai; Masaya Hattori; Takuho Okamura; Kenichi Watanabe; Takahiro Nakayama; Hiroko Masuda; Michiko Tsuneizumi; Daisuke Takabatake; Michiko Harao; Hiroshi Yoshino; Natsuko Mori; Hiroyuki Yasojima; Chiya Oshiro; Madoka Iwase; Miki Yamaguchi; Takafumi Sangai; Nobuyoshi Kosaka; Kentaro Tajima; Norikazu Masuda

  Breast cancer (Tokyo, Japan), Jul. 2024

  
• Predictive Performance of Radiomic Features Extracted from Breast MR Imaging in Postoperative Upgrading of Ductal Carcinoma in Situ to Invasive Carcinoma.

  Hiroko Satake; Fumie Kinoshita; Satoko Ishigaki; Keita Kato; Yusuke Jo; Satoko Shimada; Norikazu Masuda; Shinji Naganawa

  Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 15 May 2024

  
• Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.

  David W Cescon; Peter Schmid; Hope S Rugo; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Jose Perez-Garcia; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Amin Haiderali; Xuan Zhou; Zifang Guo; Allison Martin Nguyen; Javier Cortes

  Journal of the National Cancer Institute, 08 May 2024

  
• Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.

  Don Pietro Saldajeno; Shinpei Kawaoka; Norikazu Masuda; Sunao Tanaka; Hiroko Bando; Tomomi Nishimura; Takayuki Kadoya; Takashi Yamanaka; Shigeru Imoto; Ravindranath M Velaga; Nobuko Tamura; Tomoyuki Aruga; Kazushi Ikeda; Yukiko Fukui; Yurina Maeshima; Masahiro Takada; Eiji Suzuki; Takayuki Ueno; Seishi Ogawa; Hironori Haga; Shinji Ohno; Satoshi Morita; Kosuke Kawaguchi; Masakazu Toi

  British journal of cancer, Apr. 2024

  
• Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing

  Takeshita, T.; Iwamoto, T.; Niikura, N.; Watanabe, K.; Kikawa, Y.; Kobayashi, K.; Iwakuma, N.; Okamura, T.; Tada, H.; Ozaki, S.; Okuno, T.; Toh, U.; Yamamoto, Y.; Tsuneizumi, M.; Ishiguro, H.; Masuda, N.; Saji, S.

  ESMO Open, 2024

  
• Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

  Loibl, S.; Jassem, J.; Sonnenblick, A.; Parlier, D.; Winer, E.; Bergh, J.; Gelber, R.D.; Restuccia, E.; Im, Y.-H.; Huang, C.-S.; Dalenc, F.; Calvo, I.; Procter, M.; Caballero, C.; Clark, E.; Raimbault, A.; Mcconnell, R.; Monturus, E.; De Azambuja, E.; Gomez, H.L.; Bliss, J.; Viale, G.; Bines, J.; Piccart, M.; Aebi, S.; Andersson, M.; Bines, J.; Bonnefoi, H.; Cameron, D.; Cardoso, F.; de Haas, S.; Dent, S.; Fein, L.; Frank, E.; Gelber, R.; Gnant, M.; Gomez Moreno, H.; Im, S.-A.; Jackisch, C.; Janni, W.; Krop, I.; Kummel, S.; Liu, T.-W.; Loi, S.; Masuda, N.; Nili Gam-Yal, E.; Nyawira, B.; Pascual, T.; Pienkowski, T.; Rodr{\'i}guez-Lescure, A.; Suter, T.; Thomssen, C.; Tjan-Heijnen, V.; Tomasello, G.; Torres Ulloa, M.R.; Twelves, C.; Walshe, J.; Wilcken, N.

  Journal of Clinical Oncology, 2024

  
• Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.

  Takayuki Iwamoto; Naoki Niikura; Kenichi Watanabe; Takashi Takeshita; Yuichiro Kikawa; Kokoro Kobayashi; Nobutaka Iwakuma; Takuho Okamura; Hiroshi Tada; Shinji Ozaki; Toshitaka Okuno; Uhi Toh; Yutaka Yamamoto; Michiko Tsuneizumi; Hiroshi Ishiguro; Norikazu Masuda; Shigehira Saji

  Breast cancer research and treatment, Jan. 2024

  
• Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.

  Masato Takahashi; Tomofumi Osako; Hiroyuki Yasojima; Kenichi Inoue; Masahiro Kawashima; Hideki Maeda; Akemi Ichikawa; Yasuaki Muramatsu; Norikazu Masuda

  Breast cancer (Tokyo, Japan), Jan. 2024

  
• Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.

  Ian E Krop; Norikazu Masuda; Toru Mukohara; Shunji Takahashi; Takahiro Nakayama; Kenichi Inoue; Hiroji Iwata; Yutaka Yamamoto; Ricardo H Alvarez; Tatsuya Toyama; Masato Takahashi; Akihiko Osaki; Shigehira Saji; Yasuaki Sagara; Joyce O'Shaughnessy; Shoichi Ohwada; Kumiko Koyama; Tatsuya Inoue; Li Li; Parul Patel; Joseph Mostillo; Yoshimi Tanaka; David W Sternberg; Dalila Sellami; Kan Yonemori

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 Dec. 2023

  
• Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB).

  Shuichiro Komatsu; Masaaki Kawai; Masahiro Takada; Takahiro Nakayama; Norikazu Masuda; Hirokazu Shiheido; Zhihong Cai; Yu Jing Huang; Tsutomu Kawaguchi; Yoshinori Tanizawa

  Gan to kagaku ryoho. Cancer & chemotherapy, Dec. 2023

  
• Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.

  Toshimi Takano; Mitsuya Ito; Takayuki Kadoya; Tomofumi Osako; Tomoyuki Aruga; Norikazu Masuda; Toshiko Miyaki; Naoki Niikura; Daisuke Shimizu; Yuichi Yokoyama; Manabu Watanabe; Masato Tomomitsu; Kenjiro Aogi

  Cancer medicine, Oct. 2023

  
• Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)

  Kobayashi, K.; Masuda, N.; Mizuno, T.; Miura, K.; Tokuda, Y.; Yoshinami, T.; Kawaguchi, H.; Ohtani, S.; Saeki, T.; Toi, M.; Takeuchi, M.; Ito, Y.

  Breast Cancer Research and Treatment, Oct. 2023

  
• Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: A phase II study (WJOG11418B NEWFLAME trial)

  Masuda, J.; Sakai, H.; Tsurutani, J.; Tanabe, Y.; Masuda, N.; Iwasa, T.; Takahashi, M.; Futamura, M.; Matsumoto, K.; Aogi, K.; Iwata, H.; Hosonaga, M.; Mukohara, T.; Yoshimura, K.; Imamura, C.K.; Miura, S.; Yamochi, T.; Kawabata, H.; Yasojima, H.; Tomioka, N.; Yoshimura, K.; Takano, T.

  Journal for ImmunoTherapy of Cancer, Sep. 2023

  
• Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial

  Chiu, J.; Su, F.; Joshi, M.; Masuda, N.; Ishikawa, T.; Aruga, T.; Zarate, J.P.; Babbar, N.; Balbin, O.A.; Yap; Y.-S.

  BMC Medicine, 15 Aug. 2023

  
• Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

  Senkus, E.; Delaloge, S.; Domchek, S.M.; Conte, P.; Im, S.-A.; Xu, B.; Armstrong, A.; Masuda, N.; Fielding, A.; Robson, M.; Tung, N.

  International Journal of Cancer, 15 Aug. 2023

  
• Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06)

  Masuyama, M.; Masuda, N.; Kawaguchi, H.; Yamamoto, Y.; Saji, S.; Nakayama, T.; Aogi, K.; Anan, K.; Ohtani, S.; Sato, N.; Takano, T.; Tokunaga, E.; Nakamura, S.; Hasegawa, Y.; Hattori, M.; Fujisawa, T.; Morita, S.; Yamaguchi, M.; Yamashita, T.; Yotsumoto, D.; Toi, M.; Ohno, S.

  Cancer Medicine, 01 Aug. 2023

  Access this paper :

  
• Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).

  Manabu Futamura; Takahiro Nakayama; Tetsuhiro Yoshinami; Chiya Oshiro; Mikiya Ishihara; Midori Morita; Akira Watanabe; Azusa Tanigichi; Masami Tsukabe; Masafumi Shimoda; Kanae Nitta; Yoko Chihara; Hiroyuki Yasojima; Yoshimi Ouchi; Yoshihisa Tokumaru; Norikazu Masuda

  Breast cancer (Tokyo, Japan), 24 Jul. 2023

  
• Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355

  Hattori, M.; Masuda, N.; Takano, T.; Tsugawa, K.; Inoue, K.; Matsumoto, K.; Ishikawa, T.; Itoh, M.; Yasojima, H.; Tanabe, Y.; Yamamoto, K.; Suzuki, M.; Pan, W.; Cortes, J.; Iwata, H.

  Cancer Medicine, May 2023

  
• Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

  Holmes, F.A.; Moy, B.; Delaloge, S.; Chia, S.K.L.; Ejlertsen, B.; Mansi, J.; Iwata, H.; Gnant, M.; Buyse, M.; Barrios, C.H.; Silovski, T.; eparovi?, R.; Bashford, A.; Zotano, A.G.; Denduluri, N.; Patt, D.; Gokmen, E.; Gore, I.; Smith, J.W.; Loibl, S.; Masuda, N.; Toma?evi?, Z.; Petr{\'a}kov{\'a}, K.; DiPrimeo, D.; Wong, A.; Martin, M.; Chan, A.

  European Journal of Cancer, May 2023

  
• OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

  Robson, M.E.; Im, S.-A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Tung, N.; Armstrong, A.; Dymond, M.; Fielding, A.; Allen, A.; Conte, P.

  European Journal of Cancer, May 2023

  
• Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR⁺/HER2⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

  Massimo Cristofanilli; Hope S. Rugo; Seock-Ah Im; Dennis J. Slamon; Nadia Harbeck; Igor Bondarenko; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Hiroji Iwata; Ben O'Leary; Fabrice André; Sibylle Loibl; Eustratios Bananis; Yuan Liu; Xin Huang; Sindy Kim; Maria Jose Lechuga Frean; Nicholas C. Turner

  31 Mar. 2023

  
• Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR⁺/HER2⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

  Massimo Cristofanilli; Hope S. Rugo; Seock-Ah Im; Dennis J. Slamon; Nadia Harbeck; Igor Bondarenko; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Hiroji Iwata; Ben O'Leary; Fabrice André; Sibylle Loibl; Eustratios Bananis; Yuan Liu; Xin Huang; Sindy Kim; Maria Jose Lechuga Frean; Nicholas C. Turner

  31 Mar. 2023

  
• Supplementary Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR⁺/HER2⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

  Massimo Cristofanilli; Hope S. Rugo; Seock-Ah Im; Dennis J. Slamon; Nadia Harbeck; Igor Bondarenko; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Hiroji Iwata; Ben O'Leary; Fabrice André; Sibylle Loibl; Eustratios Bananis; Yuan Liu; Xin Huang; Sindy Kim; Maria Jose Lechuga Frean; Nicholas C. Turner

  31 Mar. 2023

  
• Supplementary Data from Overall Survival with Palbociclib and Fulvestrant in Women with HR⁺/HER2⁻ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

  Massimo Cristofanilli; Hope S. Rugo; Seock-Ah Im; Dennis J. Slamon; Nadia Harbeck; Igor Bondarenko; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Hiroji Iwata; Ben O'Leary; Fabrice André; Sibylle Loibl; Eustratios Bananis; Yuan Liu; Xin Huang; Sindy Kim; Maria Jose Lechuga Frean; Nicholas C. Turner

  31 Mar. 2023

  
• Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).

  Kenichi Watanabe; Naoki Niikura; Yuichiro Kikawa; Mari Oba; Kokoro Kobayashi; Hiroshi Tada; Shinji Ozaki; Uhi Toh; Yutaka Yamamoto; Michiko Tsuneizumi; Toshitaka Okuno; Nobutaka Iwakuma; Takashi Takeshita; Takayuki Iwamoto; Hiroshi Ishiguro; Norikazu Masuda; Shigehira Saji

  Breast cancer research and treatment, 31 Mar. 2023

  
• Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.

  Hiroji Iwata; Yutaka Yamamoto; Takehiko Sakai; Yoshie Hasegawa; Rikiya Nakamura; Hiromitsu Akabane; Shoichiro Ohtani; Masahiro Kashiwaba; Naruto Taira; Tatsuya Toyama; Tomomi Fujisawa; Norikazu Masuda; Yukiko Shibahara; Hironobu Sasano; Takuhiro Yamaguchi

  Breast cancer research and treatment, 22 Mar. 2023

  
• Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study

  Kawaguchi, H.; Yamamoto, Y.; Saji, S.; Masuda, N.; Nakayama, T.; Aogi, K.; Anan, K.; Ohtani, S.; Sato, N.; Takano, T.; Tokunaga, E.; Nakamura, S.; Hasegawa, Y.; Hattori, M.; Fujisawa, T.; Morita, S.; Yamaguchi, M.; Yamashita, T.; Yotsumoto, D.; Toi, M.; Ohno, S.

  Japanese Journal of Clinical Oncology, 07 Mar. 2023

  
• Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

  Iwata, H.; Nakamura, R.; Masuda, N.; Yamashita, T.; Yamamoto, Y.; Kobayashi, K.; Tsurutani, J.; Iwasa, T.; Yonemori, K.; Tamura, K.; Aruga, T.; Tokunaga, E.; Kaneko, K.; Lee, M.-J.; Yuno, A.; Kawabata, A.; Seike, T.; Kaneda, A.; Nishimura, Y.; Trepel, J.B.; Saji, S.

  Japanese Journal of Clinical Oncology, 06 Jan. 2023

  
• Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database

  Kawai, M.; Takada, M.; Nakayama, T.; Masuda, N.; Shiheido, H.; Cai, Z.; Huang, Y.-J.; Kawaguchi, T.; Tanizawa, Y.

  Breast Cancer Research and Treatment, Jan. 2023

  
• Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

  Udagawa, H.; Takahashi, S.; Hirao, M.; Tahara, M.; Iwasa, S.; Sato, Y.; Hamakawa, T.; Shitara, K.; Horinouchi, H.; Chin, K.; Masuda, N.; Suzuki, T.; Okumura, S.; Takase, T.; Nagai, R.; Yonemori, K.

  Cancer Medicine, Jan. 2023

  
• HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institution

  Yoshida, K.; Kotsuma, T.; Takaoka, Y.; Tamenaga, S.; Yamazaki, H.; Nose, T.; Murakami, N.; Inaba, K.; Akiyama, H.; Masui, K.; Takenaka, T.; Kubota, H.; Tselis, N.; Masuda, N.; Yasojima, H.; Takeda, M.; Mano, M.; Nakamura, S.; Utsunomiya, K.; Tanigawa, N.; Tanaka, E.

  Journal of Contemporary Brachytherapy, 2023

  
• A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer

  Takada, M.; Imoto, S.; Ishida, T.; Ito, Y.; Iwata, H.; Masuda, N.; Mukai, H.; Saji, S.; Ikeda, T.; Haga, H.; Saeki, T.; Aogi, K.; Sugie, T.; Ueno, T.; Ohno, S.; Ishiguro, H.; Kanbayashi, C.; Miyamoto, T.; Hagiwara, Y.; Toi, M.

  Breast Cancer Research and Treatment, 2023

  
• A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

  Ohsumi, S.; Nishimura, R.; Masuda, N.; Akashi-Tanaka, S.; Suemasu, K.; Yamauchi, H.; Tokunaga, E.; Ikeda, T.; Nishi, T.; Hayashi, H.; Iino, Y.; Takatsuka, Y.; Ohashi, Y.; Inaji, H.

  Breast Cancer, Jan. 2023

  
• Ⅳ. Clinical Trials on OncotypeDX-TAILORx and JBCRG-TR003 Trial

  Iwase, M.; Masuda, N.

  Gan to kagaku ryoho. Cancer & chemotherapy, 01 Dec. 2022

  
• Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer.

  Yukinori Ozaki; Junji Tsurutani; Toru Mukohara; Tsutomu Iwasa; Masato Takahashi; Yuko Tanabe; Hidetaka Kawabata; Norikazu Masuda; Manabu Futamura; Hironobu Minami; Koji Matsumoto; Kenichi Yoshimura; Shigehisa Kitano; Toshimi Takano

  Data in brief, Dec. 2022

  
• [Ⅳ. Clinical Trials on OncotypeDX-TAILORx and JBCRG-TR003 Trial].

  Iwase M; Masuda N

  Gan to kagaku ryoho. Cancer & chemotherapy, Dec. 2022

  
• Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy by PD-L1 Combined Positive Scores 1-9, 10-19, and >= 20 for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer: KEYNOTE-355 Subgroup Analysis

  Loi Sherene; Cescon DavidW; Rugo Hope S; Nowecki Zbigniew; Im Seock-Ah; Yusof Mastura Md; Gallardo Carlos; Lipatov Oleg; Barrios Carlos Henrique; Perez-Garcia Jose; Iwata Hiroji; Masuda Norikazu; Torregroza Otero Marco; Gokmen Erhan; Guo Zifang; Zhou Xuan; Karantza Vassiliki; Pan Wilbur; Schmid Peter; Cortes Javier; Douglas Julia

  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Nov. 2022

  
• Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

  Kotani, H.; Masuda, N.; Yamashita, T.; Naito, Y.; Taira, T.; Inoue, K.; Takahashi, M.; Yonemori, K.; Toyoizumi, S.; Mori, Y.; Nagasawa, T.; Hori, N.; Iwata, H.

  Breast Cancer, Nov. 2022

  
• Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)

  Saji Shigehira; Ohsumi Shozo; Ito Mitsuya; Hayashi Naoki; Kobayashi Kokoro; Masuda Norikazu; Niikura Naoki; Yamashita Toshinari; Kiyama Keiichiro; Hasegawa Ayumi; Nakagawa Shizuka; Hattori Masaya

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 06 Oct. 2022

  
• Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade

  Kobayashi, T.; Iwama, S.; Yamagami, A.; Yasuda, Y.; Okuji, T.; Ito, M.; Zhou, X.; Ando, M.; Onoue, T.; Miyata, T.; Sugiyama, M.; Hagiwara, D.; Suga, H.; Banno, R.; Hase, T.; Morise, M.; Ito, T.; Kikumori, T.; Inoue, M.; Ando, Y.; Masuda, N.; Kawashima, H.; Hashimoto, N.; Arima, H.

  Journal of Clinical Endocrinology and Metabolism, 28 Sep. 2022

  
• Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)

  Yamamoto, Y.; Iwata, H.; Taira, N.; Masuda, N.; Takahashi, M.; Yoshinami, T.; Ueno, T.; Toyama, T.; Yamanaka, T.; Takano, T.; Kashiwaba, M.; Tsugawa, K.; Hasegawa, Y.; Tamura, K.; Tada, H.; Hara, F.; Fujisawa, T.; Niikura, N.; Saji, S.; Morita, S.; Toi, M.; Ohno, S.

  Cancer Science, Sep. 2022

  
• Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG-M07 (FUTURE trial)

  Watanabe K; Niikura N; Kikawa Y; Oba M; Kobayashi K; Tada H; Ozaki S; Toh U; Yamamoto Y; Tsuneizumi M; Okuno T; Iwakuma N; Takeshita T; Iwamoto T; Ishiguro H; Masuda N; Saji S

  ANNALS OF ONCOLOGY, Sep. 2022

  
• Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)

  Ozaki Y; Kitano S; Yamashita M; Ikarashi D; Tsurutani J; Iwasa T; Takahashi M; Mukohara T; Masuda N; Futamura M; Minami H; Matsumoto K; Hashimoto Y; Tanabe; Kawabata H; Yoshimura K; Takano T

  ANNALS OF ONCOLOGY, Sep. 2022

  
• Overall Survival with Palbociclib and Fulvestrant in Women with HR^þ/HER2¯ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

  Cristofanilli, M.; Rugo, H.S.; Im, S.-A.; Slamon, D.J.; Harbeck, N.; Bondarenko, I.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Iwata, H.; O?Leary, B.; Andr{\'e}, F.; Loibl, S.; Bananis, E.; Liu, Y.; Huang, X.; Kim, S.; Frean, M.J.L.; Turner, N.C.

  Clinical Cancer Research, 15 Aug. 2022

  
• Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

  Ozaki, Y.; Tsurutani, J.; Mukohara, T.; Iwasa, T.; Takahashi, M.; Tanabe, Y.; Kawabata, H.; Masuda, N.; Futamura, M.; Minami, H.; Matsumoto, K.; Yoshimura, K.; Kitano, S.; Takano, T.

  European Journal of Cancer, Aug. 2022

  
• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

  Cortes, J.; Rugo, H.S.; Cescon, D.W.; Im, S.-A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Perez-Garcia, J.; Iwata, H.; Masuda, N.; Otero, M.T.; Gokmen, E.; Loi, S.; Guo, Z.; Zhou, X.; Karantza, V.; Pan, W.; Schmid, P.

  New England Journal of Medicine, 21 Jul. 2022

  
• Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

  Hitoshi Tsuda; Masafumi Kurosumi; Futoshi Akiyama; Shinji Ohno; Shigehira Saji; Norikazu Masuda; Akihiko Shimomura; Nobuaki Sato; Shintaro Takao; Shozo Ohsumi; Yutaka Tokuda; Hideo Inaji; Toru Watanabe

  Breast cancer (Tokyo, Japan), Jul. 2022

  
• Correction to: Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial (Breast Cancer, (2022), 29, 4, (720-729), 10.1007/s12282-022-01350-4)

  Tsuda, H.; Kurosumi, M.; Akiyama, F.; Ohno, S.; Saji, S.; Masuda, N.; Shimomura, A.; Sato, N.; Takao, S.; Ohsumi, S.; Tokuda, Y.; Inaji, H.; Watanabe, T.

  Breast Cancer, Jul. 2022

  
• KEYNOTE-355 Asian subset: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for triple-negative breast cancer

  Takano Toshimi; Cortes Javier; Cescon David W; Im Seock-Ah; Yusof Mastura Md; Iwata Hiroji; Masuda Norikazu; Huang Chiun-Sheng; Chung Chi-Feng; Tsugawa Koichiro; Park Yeon Hee; Matsumoto Koji; Inoue Kenichi; Kwong Ava; Loi Sherene; Fu Wei; Pan Wilbur; Karantza Valia; Rugo Hope S; Schmid Peter

  ANNALS OF ONCOLOGY, Jul. 2022

  
• A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months

  Yoshida, K.; Nose, T.; Otani, Y.; Asahi, S.; Tsukiyama, I.; Dokiya, T.; Saeki, T.; Fukuda, I.; Sekine, H.; Kumazaki, Y.; Takahashi, T.; Kotsuma, T.; Masuda, N.; Yoden, E.; Nakashima, K.; Matsumura, T.; Nakagawa, S.; Tachiiri, S.; Moriguchi, Y.; Itami, J.; Oguchi, M.

  Breast Cancer, Jul. 2022, Peer-reviewed

  
• Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

  Krop Ian E; Masuda Norikazu; Mukohara Toru; Takahashi Shunji; Nakayama Takahiro; Inoue Kenichi; Iwata Hiroji; Toyama Tatsuya; Yamamoto Yutaka; Hansra Damien Mikael; Takahashi Masato; Osaki Akihiko; Koyama Kumiko; Inoue Tatsuya; Yonekura Takatoshi; Mostillo Joseph; Ohwada Shoichi; Tanaka Yoshimi; Sternberg David W; Yonemori Kan

  JOURNAL OF CLINICAL ONCOLOGY, 01 Jun. 2022

  
• Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

  Masuda, N.; Ono, M.; Mukohara, T.; Yasojima, H.; Shimoi, T.; Kobayashi, K.; Harano, K.; Mizutani, M.; Tanioka, M.; Takahashi, S.; Kogawa, T.; Suzuki, T.; Okumura, S.; Takase, T.; Nagai, R.; Semba, T.; Zhao, Z.-M.; Ren, M.; Yonemori, K.

  European Journal of Cancer, Jun. 2022

  
• Observational study of axilla treatment for breast cancer patients with 1 to 3 positive micrometastases or macrometastases in sentinel lymph nodes.

  Yasojima Hiroyuki; Imoto Shigeru; Nagashima Takeshi; Onishi Tatsuya; Takashima Tsutomu; Kitada Masahiro; Kawada Masaya; Hayashida Tetsu; Naoi Yasuto; Aihara Tomohiko; Wada Noriaki; Kawabata Hidetaka; Yoshida Masayuki; Toh Uhi; Yoneyama Kimiyasu; Yamada Akimitsu; Tsuda Hitoshi; Masuda Norikazu; Saito-Oba Mari; Sakamoto Junichi

  JOURNAL OF CLINICAL ONCOLOGY, 01 Jun. 2022

  
• Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.

  Hidetoshi Kawaguchi; Yutaka Yamamoto; Shigehira Saji; Norikazu Masuda; Takahiro Nakayama; Kenjiro Aogi; Keisei Anan; Yoshinori Ito; Shoichiro Ohtani; Nobuaki Sato; Toshimi Takano; Eriko Tokunaga; Seigo Nakamura; Yoshie Hasegawa; Masaya Hattori; Tomomi Fujisawa; Satoshi Morita; Miki Yamaguchi; Hiroko Yamashita; Toshinari Yamashita; Daisuke Yotsumoto; Masakazu Toi; Shinji Ohno

  Japanese journal of clinical oncology, 31 May 2022

  
• Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial

  Saji, S.; Taira, N.; Kitada, M.; Takano, T.; Takada, M.; Ohtake, T.; Toyama, T.; Kikawa, Y.; Hasegawa, Y.; Fujisawa, T.; Kashiwaba, M.; Ishida, T.; Nakamura, R.; Yamamoto, Y.; Toh, U.; Iwata, H.; Masuda, N.; Morita, S.; Ohno, S.; Toi, M.

  The Lancet Oncology, May 2022

  
• Health-related quality of life (HRQoL) with pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355

  Cescon D. W; Schmid P; Rugo H. S; Im S-A; Yusof M. Md; Gallardo C. E; Lipatov O; Barrios C. H; Perez Garcia J. M; Iwata H; Masuda N; Torregroza Otero M. A; Gokmen E; Loi S; Haiderali A; Zhou X; Guo Z; Nguyen A. Martin; Cortes J

  ANNALS OF ONCOLOGY, May 2022

  
• Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

  Ueno, T.; Kitano, S.; Masuda, N.; Ikarashi, D.; Yamashita, M.; Chiba, T.; Kadoya, T.; Bando, H.; Yamanaka, T.; Ohtani, S.; Nagai, S.; Nakayama, T.; Takahashi, M.; Saji, S.; Aogi, K.; Velaga, R.; Kawaguchi, K.; Morita, S.; Haga, H.; Ohno, S.; Toi, M.

  BMC Medicine, 25 Apr. 2022

  
• Effect of proximal optimization technique on coronary bifurcation stent failure: Insights from the multicenter randomized PROPOT trial

  Murasato Y; Watanabe Y; Yamawaki M; Kinoshita Y; Okubo M; Yumoto K; Masuda N; Otake H; Aoki J; Nakazawa G; Numasawa Y; Ito T; Shite J; Okamura T; Takagi K; Kozuma K; Lefèvre T; Chevalier B; Louvard Y; Suzuki N; Kozuma K

  Catheterization and Cardiovascular Interventions, 01 Mar. 2022

  
• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Geyer, C.E.; Garber, J.E.; Gelber, R.D.; Yothers, G.; Taboada, M.; Ross, L.; Rastogi, P.; Cui, K.; Arahmani, A.; Aktan, G.; Armstrong, A.C.; Arnedos, M.; Balma{\~n}a, J.; Bergh, J.; Bliss, J.; Delaloge, S.; Domchek, S.M.; Eisen, A.; Elsafy, F.; Fein, L.E.; Fielding, A.; Ford, J.M.; Friedman, S.; Gelmon, K.A.; Gianni, L.; Gnant, M.; Hollingsworth, S.J.; Im, S.-A.; Jager, A.; J{\'o}hannsson, ?; Lakhani, S.R.; Janni, W.; Linderholm, B.; Liu, T.-W.; Loman, N.; Korde, L.; Loibl, S.; Lucas, P.C.; Marm{\'e}, F.; Martinez de Due; n}as, E.; McConnell, R.; Phillips, K.-A.; Piccart, M.; Rossi, G.; Schmutzler, R.; Senkus, E.; Shao, Z.; Sharma, P.; Singer, C.F.; pani?, T.; Stickeler, E.; Toi, M.; Traina, T.A.; Viale, G.; Zoppoli, G.; Park, Y.H.; Yerushalmi, R.; Yang, H.; Pang, D.; Jung, K.H.; Mailliez, A.; Fan, Z.; Tennevet, I.; Zhang, J.; Nagy, T.; Sonke, G.S.; Sun, Q.; Parton, M.; Colleoni, M.A.; Schmidt, M.; Brufsky, A.M.; Razaq, W.; Kaufman, B.; Cameron, D.; Campbell, C.; Tutt, A.N.J.; Sevelda, P.; Haslbauer, F.; Penzinger, M.; O}hler, L.; Tinchon, C.; Greil, R.; Heibl, S.; Bartsch, R.; Wette, V.; Singer, C.F.; Pasterk, C.; Helfgott, R.; Pristauz-Telsnigg, G.; St{\"o}ger, H.; Weltermann, A.; Egle, D.; Thiel, I.; Fuchs, D.; Rumpold, H.; Strasser-Weippl, K.; Rautenberg, B.; M{\"u}ller, V.; Schmidt, M.; Paepke, S.; Aydogdu, M.; Thomssen, C.; Rom, J.; Mau, C.; Fasching, P.; G{\"o}hring, U.-J.; K{\"u}hn, T.; Noeding, S.; K; u}mmel, S.; Hackmann, J.; Stickeler, E.; Joshi, A.; Dewar, J.; Friedlander, M.; Antill, Y.; Woodward, N.; Abdi, E.; Tiley, S.; George, M.; Boadle, D.; Goodwin, A.; van der Westhuizen, A.; Kannourakis, G.; Murray, N.; McCarthy, N.; Kroep, J.; de Boer, M.; Heijns, J.; Erdkamp, F.; Bakker, S.; Sonke, G.S.; Sami, A.; Mackey, J.; Prady, C.; Eisen, A.; Desbiens, C.; Patocskai, E.; Ferrario, C.; Bordeleau, L.; Chalchal, H.; Niraula, S.; ido wolf; Duhoux, F.; Randal d{'}Hond; Luce, S.; Roodenbeke; D.T.D.; Papadimitriou, K.; Borms, M.; Quaghebeur, C.; Jacot, W.; Brain, E.; Venat-Bouvet, L.; Lortholary, A.; Nowecki, Z.; Cardoso, F.; Hayward, R.; Bella, S.; Lazzaro, M.F.; Pilnik, N.; Fein, L.E.; Blajman, C.; Lerzo, G.; Varela, M.; Zarba, J.J.; Kaen, D.; Constanzo, M.V.; Tio, J.; Siggelkow, W.; Jackisch, C.; Grischke, E.M.; Zahm, D.; Tato-Varela, S.; Schmatloch, S.; Klare, P.; Stefek, A.; Rhiem, K.; Hoffmann, O.; Deryal, M.; Gr{\"o}ll, I.; Ledwon, P.; Uleer, C.; Krabisch, P.; Potenberg, J.; Darsow, M.; Park-Simon, T.-W.; H{\"o}ffkes, H.-G.; Emde, T.-O.; Graffunder, G.; Tom{\'e}, O.; Forstmeyer, D.; Terhaag, J.; Salat, C.; Kast, K.; Weniger, S.; Schreiber, C.; Heinrich, B.; Dieterich, M.; W{\"u}llner, M.P.; Conejero, R.A.; Garc{\'i}a; S{\'a}enz, J.; Martinez, L.C.; Lanza, A.A.; Murillo, S.M.; Carrasco, F.H.; Tormo, S.B.; L{\'o}pez, I.?; Delgado Mingorance, J.I.; Gomez, E.?; Santisteban, M.; Jurado, J.C.; Quiroga, V.; Borrego, M.R.; Mart{\'i}nez de Due; n}as, E.; Al{\'e}s Mart{\'i}nez, J.E.; De la Haba, J.; Ja{\~n}ez, N.M.; Lescure, ?.R.; Torres, A.A.; Crusades, G.L.; Gonz{\'a}lez-Santiago, S.; Aragones, A.M.; Ortega, A.L.; Molins, A.B.; Chac{\'o}n L{\'o}pez-Mu{\~n}iz, J.I.; Jim{\'e}nez, M.M.; Bertr{\'a}n, A.S.; Rodr{\'i}guez, C.; Cortijo, L.G.; Cretella, E.; Cortesi, L.; Ruggeri, E.M.; Verusio, C.; Gori, S.; Bonetti, A.; Mosconi, A.M.; Johannsson, O.; Jerusalem, G.; Neven, P.; Nagy, T.; Pinotti, G.; Colleoni, M.A.; Bernardo, A.; Gianni, L.; Bucci, E.; Biganzoli, L.; Dedes, K.; Novak, U.; Zaman, K.; Braybrooke, J.; Winter, M.; Rea, D.; Kelleher, M.; Barrett, S.; Chan, S.; Hickish, T.; Hurwitz, J.; Conibear, J.; Jegannathen, A.; Parton, M.; Tutt, A.; Allerton, R.; Borley, A.; Armstrong, A.; Copson, E.; Levitt, N.; Abraham, J.; Perren, T.; Roylance, R.; Ishida, K.; Toyama, T.; Masuda, N.; Watanabe, J.; Tokunaga, E.; Kinoshita, T.; Rai, Y.; Takada, M.; Yanagita, Y.; Nakamura, R.; Nakayama, T.; Naoi, Y.; Iwata, H.; Nakamura, S.; Takahashi, M.; Aogi, K.; Tsugawa, K.; Mukai, H.; Takano, T.; Osaki, A.; Sato, N.; Yamauchi, H.; Tokuda, Y.; Ito, M.; Sugimoto, T.; Bahadur, S.W.; Ganz, P.A.; Lu, M.J.; Mita, M.M.; Waisman, J.; Polikoff, J.A.; Telli, M.L.; Seaward, S.A.; Suga, J.M.; Durna, L.N.; Carney, J.F.; Menter, A.; Puthillath, A.; Rohatgi, N.; Feusner, J.H.; Bobolis, K.A.; Eisenberg, P.D.; Wong, D.; Borges, V.F.; Urquhart, A.T.; Hofstatter, E.W.; McCarron, E.C.; Isaacs, C.; Herbolsheimer, P.; Varadarajan, R.; Raben, A.; Deveras, R.A.E.; Valdes-Albini, F.; Mahtani, R.L.; Meisel, J.L.; Sumrall, B.T.; Jones, C.F.; Ofori, S.N.; Sumida, K.N.M.; Karwal, M.; Wilbur, D.W.; Singh, J.; Spector, D.M.; Schallenkamp, J.; Merkel, D.E.; Lo, S.S.; Khosla, P.G.; Cristofanilli, M.; Flaum, L.; Hoskins, K.F.; Cobleigh, M.A.; Lambiase, E.A.; Hahn, O.M.; Oliff, I.A.; Faller, B.A.; Wade, J.L.; Burhani, N.D.; Gil, A.; Einhorn, H.E.; Storniolo, A.M.V.; Chang, B.K.; Kalra, M.; Robin, E.L.; Ansari, B.; Sharma, P.; Dakhil, S.R.; Deming, R.L.; Cole, J.T.; Hanson, D.S.; Ochoa, A.C.; Garber, J.E.; Zimbler, H.; Armstrong, D.K.; Tkaczuk, K.H.R.; Riseberg, D.A.; O{'}Connor, B.M.; Openshaw, T.H.; Zakalik, D.; Vakhariya, C.M.; Schott, A.F.; Simon, M.S.; Doyle, T.J.; Al Baghdadi, T.; VanderWoude, A.; Flynn, P.J.; Zera, R.T.; Friday, B.E.B.; Ruddy, K.J.; Smith, R.; Ademuyiwa; Olabisi, F.; Ellis, R.; Carlson, J.W.; Marchello; T, B.; Levine, E.A.; Marcom, P.K.; Harkness, C.B.; Tan, A.R.; Charles, W.J.; Kuzma, C.S.; Asaad, S.; Radford, J.E.; Steen, P.D.; Unnikrishnan, M.; Seeger, G.R.; Leu, K.M.H.; Copur, M.S.; Hauke, R.J.; Soori, G.S.; Arrick, B.A.; Reeder, J.G.; Toppmeyer, D.L.; Dayao, Z.R.; Adams, S.; Andreopoulou, E.; Allison, M.; Anampa Mesias, J.D.; Sharma, R.; Ramaswamy, B.; Gerds, A.T.; Shenk, R.R.; Gross, H.M.; Trehan, S.; Razaq, W.; Mansoor, A.H.; Hilton, C.J.; Brufsky, A.M.; Huynh, C.; Chowdhury, N.; Domchek, S.M.; Sigurdson, E.R.; Cescon, T.P.; Rovito, M.A.; DeNittis, A.S.; Vogel, V.G.; Julian, T.B.; Boyle, L.E.; Baez-Diaz, L.; Brescia, F.J.; Doster, J.E.; Siegel, R.D.; Wong, L.; Patel, T.; Nangia, J.R.; Jones, C.A.; Cannon, G.M.; Bear, H.D.; Vachhani, H.; Wilkinson, M.; Wood, M.E.; Yan, F.; Sui, X.; van Haelst, C.M.; Specht, J.M.; Zhuo, Y.; Qamar, R.; Ryan, M.L.; Stockham, A.; Virani, S.; Gayle, A.A.; Jubelirer, S.J.; Kurian, S.; Salkeni, M.A.; Loman, N.; Linderholm, B.; Silander, G.; Hallbeck, A.-L.; von Wachenfeldt V{\"a}ppling, A.; Curtit, E.; Cardoso, C.; Braga, S.; Abreu, M.; Casa-Nova, M.; Nave, M.; Ciruelos Gil, E.M.; Gelpi, J.B.; Ortega, A.F.; Padr{\'o}, J.G.; Bermejo de las; Heras, B.; Cao, M.G.; Ba{\~n}uelos, J.C.; Company, J.A.; Villar{\'o}, G.V.; Estevez, L.G.; Huober, J.; Busch, S.; Fehm, T.; Hahn, A.; Grafe, A.; Noesselt, T.; Dewitz, T.; Wagner, H.; Bechtner, C.; Weigel, M.; Kolberg, H.-C.; Decker, T.; Thomalla, J.; Hesse, T.; Harbeck, N.; Jens-Uwe Blohmer, J.S.; Wolf S.; erlin, M.; Altena, R.; Chiu, C.-F.; Chen, S.-C.; Hou, M.-F.; Chang, Y.-C.; Chen, S.-H.; Chen, S.-T.; Huang, C.-S.; and Yeh; D.-C.; Yu, J.-C.; Tseng, L.-M.; Chung, W.-P.; Mailliez, A.; Petit, T.; Delaloge, S.; L{\'e}vy, C.; Dalivoust, P.; Extra, J.-M.; Mouret-Reynier, M.-A.; Hardy-Bessard, A.-C.; Simon, H.; Haridon, T.; Mege, A.; Giacchetti, S.; Chakiba-Brugere, C.; Gratet, A.; Pottier, V.; Ferrero, J.-M.; Tennevet, I.; Perrin, C.; Canon, J.-L.; Joris, S.; Shao, Z.; Xu, B.; Jiang, Z.; Sun, Q.; Shen, K.; Pang, D.; Zhang, J.; Wang, S.; Yang, H.; Liao, N.; Zheng, H.; Fu, P.; Song, C.; Wang, Y.; Fan, Z.; Geng, C.; Tredan, O.; Landherr, L.; Kaufman, B.; Yerushalmi, R.; Uziely, B.; Conte, P.; Zamagni, C.; Bianchini, G.; De Laurentiis, M.; Tondini, C.; Gebbia, V.; Ciccarese, M.; Sarosiek, T.; Mackiewicz, J.; S?owi?ska, A.; Kalinka, E.; Huzarski, T.; Im, S.-A.; Sohn, J.H.; Kim, J.H.; Lee, K.S.; Park, Y.H.; Lee, K.E.; Chae, Y.S.; Cho, E.K.

  Annals of Oncology, 2022

  
• Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (International Journal of Clinical Oncology, (2021), 26, 7, (1229-1236), 10.1007/s10147-021-01920-0)

  Aogi, K.; Watanabe, K.; Kitada, M.; Sangai, T.; Ohtani, S.; Aruga, T.; Kawaguchi, H.; Fujisawa, T.; Maeda, S.; Morimoto, T.; Sato, N.; Takao, S.; Morita, S.; Masuda, N.; Toi, M.; Ohno, S.

  International Journal of Clinical Oncology, 2022

  
• Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

  Masuda, N.; Chen, Y.; Kawaguchi, T.; Dozono, K.; Toi, M.

  Cancer Management and Research, 2022

  
• Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer

  Kosaka, Y.; Saeki, T.; Takano, T.; Aruga, T.; Yamashita, T.; Masuda, N.; Koibuchi, Y.; Osaki, A.; Watanabe, J.; Suzuki, R.

  International Journal of Nanomedicine, 2022

  
• Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data.

  Norikazu Masuda; Nobuyoshi Kosaka; Hiroji Iwata; Masakazu Toi

  International journal of clinical oncology, Dec. 2021

  
• [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].

  Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S

  Gan to kagaku ryoho. Cancer & chemotherapy, Dec. 2021, Peer-reviewed

  
• A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

  Fukada I; Ito Y; Kondo N; Ohtani S; Hattori M; Tokunaga E; Matsunami N; Mashino K; Kosaka T; Tanabe M; Yotsumoto D; Yamanouchi K; Sawaki M; Kashiwaba M; Kawabata H; Kuroi K; Morita S; Ohno S; Toi M; Masuda N

  Breast Cancer Research and Treatment, Dec. 2021

  
• Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

  Masuda, N.; Tamura, K.; Yasojima, H.; Shimomura, A.; Sawaki, M.; Lee, M.-J.; Yuno, A.; Trepel, J.; Kimura, R.; Nishimura, Y.; Saji, S.; Iwata, H.

  BMC Cancer, 24 Nov. 2021, Peer-reviewed, Lead author, Corresponding author

  
• MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.

  Patrick Neven; Stephen R D Johnston; Masakazu Toi; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Nadine Haddad; Karla C Hurt; Antonio Llombart-Cussac; George W Sledge

  Clinical cancer research : an official journal of the American Association for Cancer Research, 01 Nov. 2021

  
• Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.

  Ming Shen Dai; Yin Hsun Feng; Shang Wen Chen; Norikazu Masuda; Thomas Yau; Shou Tung Chen; Yen Shen Lu; Yoon Sim Yap; Peter C S Ang; Sung Chao Chu; Ava Kwong; Keun Seok Lee; Samuel Ow; Sung Bae Kim; Johnson Lin; Hyun Cheol Chung; Roger Ngan; Victor C Kok; Kun Ming Rau; Takafumi Sangai; Ting Ying Ng; Ling Ming Tseng; Richard Bryce; Judith Bebchuk; Mei Chieh Chen; Ming Feng Hou

  Breast cancer research and treatment, Oct. 2021

  
• Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.

  Kenichi Inoue; Norikazu Masuda; Hiroji Iwata; Masato Takahashi; Yoshinori Ito; Yasuo Miyoshi; Takahiro Nakayama; Hirofumi Mukai; Jan-Stefan van der Walt; Joji Mori; Sachi Sakaguchi; Tsutomu Kawaguchi; Yoshinori Tanizawa; Antonio Llombart-Cussac; George W Sledge Jr; Masakazu Toi

  Breast cancer (Tokyo, Japan), Sep. 2021

  Access this paper :

  
• Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).

  Manabu Futamura; Mari Oba; Norikazu Masuda; Hiroko Bando; Morihito Okada; Yutaka Yamamoto; Takanori Kin; Toshiaki Saeki; Takeshi Nagashima; Takashi Kuwayama; Uhi Toh; Akira Hirano; Masafumi Inokuchi; Kazuhiko Yamagami; Yutaka Mizuno; Yasuyuki Kojima; Takahiro Nakayama; Hiroyuki Yasojima; Shinji Ohno

  Breast cancer (Tokyo, Japan), Sep. 2021

  
• Capecitabine in combination with endocrine therapy as maintenance therapy after bevacizumab plus paclitaxel induction therapy for hormone receptor-positive, her2-negative metastatic breast cancer: Kbcsg-tr1214

  Masuda, N.; Yoshinami, T.; Ikeda, M.; Mizutani, M.; Yamaguchi, M.; Komoike, Y.; Takashima, T.; Yoshidome, K.; Tsurutani, J.; Iwamoto, M.; Fujisawa, F.; Yasojima, H.; Yamamura, J.; Morishima, H.; Aki, F.; Yamada, T.; Morita, S.; Nakayama, T.

  Cancers, 31 Aug. 2021, Lead author, Corresponding author

  
• Long-term outcomes of a randomized study of neoadjuvant induction dual her2 blockade with trastuzumab and lapatinib followed by weekly paclitaxel plus dual her2 blockade for her2-positive primary breast cancer (Neo-lath study)

  Tokunaga, E.; Masuda, N.; Yamamoto, N.; Iwata, H.; Bando, H.; Aruga, T.; Ohtani, S.; Fujisawa, T.; Takano, T.; Inoue, K.; Suganuma, N.; Takada, M.; Aogi, K.; Sakurai, K.; Shigematsu, H.; Kuroi, K.; Haga, H.; Ohno, S.; Morita, S.; Toi, M.

  Cancers, 09 Aug. 2021, Peer-reviewed, Corresponding author

  
• Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

  Nakayama, T.; Yoshinami, T.; Yasojima, H.; Kittaka, N.; Takahashi, M.; Ohtani, S.; Kim, S.J.; Kurakami, H.; Yamamoto, N.; Yamada, T.; Takata, T.; Masuda, N.

  BMC Cancer, 09 Jul. 2021, Peer-reviewed, Last author

  
• Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.

  Norikazu Masuda; Hiroko Bando; Takashi Yamanaka; Takayuki Kadoya; Masato Takahashi; Shigenori E Nagai; Shoichiro Ohtani; Tomoyuki Aruga; Eiji Suzuki; Yuichiro Kikawa; Hiroyuki Yasojima; Hiroi Kasai; Hiroshi Ishiguro; Hidetaka Kawabata; Satoshi Morita; Hironori Haga; Tatsuki R Kataoka; Ryuji Uozumi; Shinji Ohno; Masakazu Toi

  Breast cancer research and treatment, Jul. 2021

  
• In Reply.

  Hope S Rugo; Jens Huober; Jose A Garcia-Saenz; Norikazu Masuda; Joo Hyuk Sohn; Valerie A M Andre; Susana Barriga; Joanne Cox; Matthew Goetz

  The oncologist, Jul. 2021

  
• Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

  Kenjiro Aogi; Kenichi Watanabe; Masahiro Kitada; Takafumi Sangai; Shoichiro Ohtani; Tomoyuki Aruga; Hidetoshi Kawaguchi; Tomomi Fujisawa; Shigeto Maeda; Takashi Morimoto; Nobuaki Sato; Shintaro Takao; Satoshi Morita; Norikazu Masuda; Masakazu Toi; Shinji Ohno

  International journal of clinical oncology, Jul. 2021

  
• Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

  Kenjiro Aogi; Kenichi Watanabe; Masahiro Kitada; Takafumi Sangai; Shoichiro Ohtani; Tomoyuki Aruga; Hidetoshi Kawagichi; Tomomi Fujisawa; Shigeto Maeda; Takashi Morimoto; Nobuaki Sato; Shintaro Takao; Satoshi Morita; Norikazu Masuda; Masakazu Toi; Shinji Ohno

  International journal of clinical oncology, Jul. 2021

  
• Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study

  Tanaka, K.; Masuda, N.; Hayashi, N.; Sagara, Y.; Hara, F.; Kadoya, T.; Matsui, A.; Miyazaki, C.; Shien, T.; Tokunaga, E.; Hayashi, T.; Niikura, N.; Maeda, S.; Komoike, Y.; Bando, H.; Kanbayashi, C.; Iwata, H.

  Breast Cancer, Jul. 2021, Peer-reviewed

  
• Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.

  Eva Maria Ciruelos; Hope S Rugo; Ingrid A Mayer; Christelle Levy; Frédéric Forget; Juan Ignacio Delgado Mingorance; Tamar Safra; Norikazu Masuda; Yeon Hee Park; Dejan Juric; Pierfranco Conte; Mario Campone; Sibylle Loibl; Hiroji Iwata; Xiaolei Zhou; Jinhee Park; Antonia Ridolfi; Ines Lorenzo; Fabrice André

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 Jun. 2021

  
• Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.

  Masakazu Toi; Kenichi Inoue; Norikazu Masuda; Hiroji Iwata; Joohyuk Sohn; In Hae Park; Seock-Ah Im; Shin-Cheh Chen; Sotaro Enatsu; P Kellie Turner; Valérie A M André; Molly C Hardebeck; Sachi Sakaguchi; Matthew P Goetz; George W Sledge Jr

  Cancer science, Jun. 2021

  
• Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.

  Norikazu Masuda; Hirofumi Mukai; Kenichi Inoue; Yoshiaki Rai; Shinji Ohno; Shoichiro Ohtani; Chikako Shimizu; Satoshi Hashigaki; Yasuaki Muramatsu; Yoshiko Umeyama; Hiroji Iwata; Masakazu Toi

  Breast cancer (Tokyo, Japan), Mar. 2021

  
• Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.

  Hope S Rugo; Jens Huober; José A García-Sáenz; Norikazu Masuda; Joo Hyuk Sohn; Valerie A M Andre; Susana Barriga; Joanne Cox; Matthew Goetz

  The oncologist, Mar. 2021

  
• Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).

  Toshinari Yamashita; Hidetoshi Kawaguchi; Norikazu Masuda; Masahiro Kitada; Kazutaka Narui; Masaya Hattori; Tetsuhiro Yoshinami; Nobuki Matsunami; Kazuhiro Yanagihara; Teru Kawasoe; Takeshi Nagashima; Hiroko Bando; Hiroshi Yano; Yoshie Hasegawa; Rikiya Nakamura; Masahiro Kashiwaba; Satoshi Morita; Shinji Ohno; Masakazu Toi

  Investigational new drugs, Feb. 2021

  
• Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.

  Yoko Otani; Kiyoshi Mori; Nozomi Morikawa; Makiko Mizutani; Hiroyuki Yasojima; Misato Masuyama; Masayuki Mano; Norikazu Masuda

  Immunotherapy, Feb. 2021

  
• Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).

  Shinji Ohno; Shigehira Saji; Norikazu Masuda; Hitoshi Tsuda; Futoshi Akiyama; Masafumi Kurosumi; Akihiko Shimomura; Nobuaki Sato; Shintaro Takao; Shozo Ohsumi; Yutaka Tokuda; Hideo Inaji; Toru Watanabe; Yasuo Ohashi

  Breast cancer research and treatment, Feb. 2021

  
• Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer

  Masuda, N.; Saji, S.; Kawaguchi, T.; Chen, Y.; Ohno, S.

  Gan to kagaku ryoho. Cancer & chemotherapy, 2021

  
• The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.

  Masato Takahashi; Shoichiro Ohtani; Shigenori E Nagai; Seiki Takashima; Miki Yamaguchi; Michiko Tsuneizumi; Yoshifumi Komoike; Tomofumi Osako; Yoshinori Ito; Masahiko Ikeda; Kazushige Ishida; Takahiro Nakayama; Tsutomu Takashima; Takashi Asakawa; Sho Matsumoto; Daisuke Shimizu; Norikazu Masuda

  Breast cancer research and treatment, Jan. 2021

  
• Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.

  Hope S Rugo; Jens Huober; José A García-Sáenz; Norikazu Masuda; Joo Hyuk Sohn; Valerie A M Andre; Susana Barriga; Joanne Cox; Matthew Goetz

  The oncologist, Jan. 2021

  
• Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

  Toi, M.; Imoto, S.; Ishida, T.; Ito, Y.; Iwata, H.; Masuda, N.; Mukai, H.; Saji, S.; Shimizu, A.; Ikeda, T.; Haga, H.; Saeki, T.; Aogi, K.; Sugie, T.; Ueno, T.; Kinoshita, T.; Kai, Y.; Kitada, M.; Sato, Y.; Jimbo, K.; Sato, N.; Ishiguro, H.; Takada, M.; Ohashi, Y.; Ohno, S.

  The Lancet Oncology, Jan. 2021, Peer-reviewed

  
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

  Javier Cortes; David W Cescon; Hope S Rugo; Zbigniew Nowecki; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Esther Holgado; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Zifang Guo; Jing Zhao; Gursel Aktan; Vassiliki Karantza; Peter Schmid

  Lancet (London, England), 05 Dec. 2020, Peer-reviewed

  
• [Ⅰ.Capecitabine for Adjuvant Therapy in Breast Cancer].

  Norikazu Masuda

  Gan to kagaku ryoho. Cancer & chemotherapy, Dec. 2020, Peer-reviewed, Invited, Lead author

  
• Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.

  Moe Tsuda; Hiroshi Ishiguro; Naoko Toriguchi; Norikazu Masuda; Hiroko Bando; Masahiro Ohgami; Masato Homma; Satoshi Morita; Naohito Yamamoto; Katsumasa Kuroi; Yasuhiro Yanagita; Toshimi Takano; Satoru Shimizu; Masakazu Toi

  Cancer medicine, Dec. 2020

  
• Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.

  Cristina Saura; Mafalda Oliveira; Yin-Hsun Feng; Ming-Shen Dai; Shang-Wen Chen; Sara A Hurvitz; Sung-Bae Kim; Beverly Moy; Suzette Delaloge; William Gradishar; Norikazu Masuda; Marketa Palacova; Maureen E Trudeau; Johanna Mattson; Yoon Sim Yap; Ming-Feng Hou; Michelino De Laurentiis; Yu-Min Yeh; Hong-Tai Chang; Thomas Yau; Hans Wildiers; Barbara Haley; Daniele Fagnani; Yen-Shen Lu; John Crown; Johnson Lin; Masato Takahashi; Toshimi Takano; Miki Yamaguchi; Takaaki Fujii; Bin Yao; Judith Bebchuk; Kiana Keyvanjah; Richard Bryce; Adam Brufsky

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 Sep. 2020

  
• Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.

  Yoon-Sim Yap; Joanne Chiu; Yoshinori Ito; Takashi Ishikawa; Tomoyuki Aruga; Seung Jin Kim; Tatsuya Toyama; Toshiaki Saeki; Mitsue Saito; Ioannis Gounaris; Fei Su; Yan Ji; Yu Han; Mihaela Gazdoiu; Norikazu Masuda

  Cancer science, 01 Sep. 2020

  
• Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.

  Hiroyasu Yamashiro; Hiroji Iwata; Norikazu Masuda; Naohito Yamamoto; Reiki Nishimura; Shoichiro Ohtani; Nobuaki Sato; Masato Takahashi; Takako Kamio; Kosuke Yamazaki; Tsuyoshi Saito; Makoto Kato; Tecchuu Lee; Katsumasa Kuroi; Toshimi Takano; Shinji Yasuno; Satoshi Morita; Shinji Ohno; Masakazu Toi

  Breast cancer (Tokyo, Japan), Jul. 2020

  
• Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.

  Masato Takahashi; Norikazu Masuda; Reiki Nishimura; Kenichi Inoue; Shinji Ohno; Hiroji Iwata; Satoshi Hashigaki; Yasuaki Muramatsu; Yoshiko Umeyama; Masakazu Toi

  Cancer medicine, Jul. 2020

  
• Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).

  Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno

  Trials, 08 Jun. 2020

  
• Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.

  Seock-Ah Im; Binghe Xu; Wei Li; Mark Robson; Quchang Ouyang; Dah-Cherng Yeh; Hiroji Iwata; Yeon Hee Park; Joo Hyuk Sohn; Ling-Ming Tseng; Carsten Goessl; Wenting Wu; Norikazu Masuda

  Scientific reports, 29 May 2020

  
• Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).

  Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno

  Trials, 07 May 2020

  
• Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

  Hidetoshi Kawaguchi; Norikazu Masuda; Takahiro Nakayama; Kenjiro Aogi; Keisei Anan; Yoshinori Ito; Shoichiro Ohtani; Nobuaki Sato; Shigehira Saji; Toshimi Takano; Eriko Tokunaga; Seigo Nakamura; Yoshie Hasegawa; Masaya Hattori; Tomomi Fujisawa; Satoshi Morita; Miki Yamaguchi; Hiroko Yamashita; Toshinari Yamashita; Yutaka Yamamoto; Daisuke Yotsumoto; Masakazu Toi; Shinji Ohno

  Breast cancer (Tokyo, Japan), May 2020

  
• A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.

  Hiroshi Ishiguro; Norikazu Masuda; Nobuaki Sato; Kenji Higaki; Takashi Morimoto; Yasuhiro Yanagita; Makiko Mizutani; Shoichiro Ohtani; Koji Kaneko; Tomomi Fujisawa; Masato Takahashi; Takayuki Kadoya; Nobuki Matsunami; Yutaka Yamamoto; Shinji Ohno; Toshimi Takano; Satoshi Morita; Sachiko Tanaka-Mizuno; Masakazu Toi

  Breast cancer research and treatment, Apr. 2020

  
• Breast metastasis from rectal cancer with BRAF V600E mutation: a case report with a review of the literature.

  Hiroko Hasegawa; Yoko Nagata; Yuko Sakakibara; Masakazu Miyake; Kiyoshi Mori; Norikazu Masuda; Masayuki Mano; Shoichi Nakazuru; Hisashi Ishida; Eiji Mita

  Clinical journal of gastroenterology, Apr. 2020

  
• Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.

  Madoka Iwase; Masashi Ando; Kenjiro Aogi; Tomoyuki Aruga; Kenichiro Inoue; Akihiko Shimomura; Eriko Tokunaga; Norikazu Masuda; Hideko Yamauchi; Toshinari Yamashita; Hiroji Iwata

  Breast cancer research and treatment, Apr. 2020

  
• Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.

  Johannes Ettl; Seock-Ah Im; Jungsil Ro; Norikazu Masuda; Marco Colleoni; Patrick Schnell; Eustratios Bananis; Dongrui R Lu; Massimo Cristofanilli; Hope S Rugo; Richard S Finn

  Breast cancer research : BCR, 12 Mar. 2020

  
• A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.

  Norikazu Masuda; Shoichiro Ohtani; Toshimi Takano; Kenichi Inoue; Eiji Suzuki; Rikiya Nakamura; Hiroko Bando; Yoshinori Ito; Kazushige Ishida; Takashi Yamanaka; Katsumasa Kuroi; Hiroyuki Yasojima; Hiroi Kasai; Tsuyoshi Takasuka; Takaki Sakurai; Tatsuki R Kataoka; Satoshi Morita; Shinji Ohno; Masakazu Toi

  Breast cancer research and treatment, Feb. 2020

  
• Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.

  Takayuki Ueno; Norikazu Masuda; Nobuaki Sato; Shoichiro Ohtani; Jun Yamamura; Nobuki Matsunami; Masahiro Kashiwaba; Toshimi Takano; Masato Takahashi; Koji Kaneko; Shinji Ohno; Satoshi Morita; Masakazu Toi

  Japanese journal of clinical oncology, 24 Jan. 2020

  
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

  Swain, S.M.; Miles, D.; Kim, S.-B.; Im, Y.-H.; Im, S.-A.; Semiglazov, V.; Ciruelos, E.; Schneeweiss, A.; Loi, S.; Monturus, E.; Clark, E.; Knott, A.; Restuccia, E.; Benyunes, M.C.; Cort{\'e}s, J.; Agajanian, R.; Ahmad, R.; Aktas, B.; Alencar, V.H.; Amadori, D.; Andrade, J.; Andr{\'e; Franke, F.; Angiolini, C.; Aogi, K.; Armor, J.; Arpornwirat, W.; Assersohn, L.; Audeh, W.; Aulitzky, W.; Azevedo, S.; Bartoli, M.A.; Batista Lopez, N.; Bianconi, M.; Biganzoli, L.; Birhiray, R.; Bitina, M.; Blachy, R.; Blackwell, K.; Blanchard, R.; Blanchet, P.; Boiangiu, I.; Bower, B.; Brezden-Masley, C.; Brufsky, A.; Budde, L.; Caguioa, P.; Calvo, L.; Campone, M.; Carroll, R.R.; Castro, H.; Chan, V.; Charu, V.; Cinieri, S.; Clemens, M.; Conejo, E.A.; C{\^o}rtes, E.; Coudert, B.; Cronemberger, E.; Cubero, D.; Dakhil, S.; Daniel, B.; Davidson, N.; De Fatima Gaui, M.; De La Cruz, S.; Del Pilar, M.; Delgado, G.; Ellerton, J.A.; Estuardo, C.; Fehrenbacher, L.; Ferrero, J.-M.; Flynn, P.J.; Foszczynska-Kloda, M.; Franco, S.; Fujii, H.; Gallagher, C.; Gamucci, T.; Giacomi, N.; Gil I Gil, M.; Gonzalez Martin, A.; Gorbunova, V.; Gotovkin, E.; Green, N.; Grincuka, E.; Grischke, E.-M.; Hansen, V.; Hargis, J.; Hauschild, M.; Hegg, R.; Hendricks, C.; Hermann, R.; Hoff, P.; Horiguchi, J.; Hornedo Muguiro, J.; Iacobelli, S.; Inoue, K.; Ismael, G.; Itoh, Y.; Iwata, D.H.; Jendiroba, D.; Jochim, R.; Jones, A.; Just, M.; Kallab, A.; Karwal, M.; Kashiwaba, M.; Kato, G.; Kaufman, P.A.; Kellokumpu-Lehtinen, P.; Kirsch, A.; Kiselev, I.; Klein, P.; Kohno, N.; Kopp, M.; Kostovska-Maneva, L.; Kotliar, M.; Kudaba, I.; K; u}mmel, S.; Kuroi, K.; Lacava, J.; Latini, L.; Lee, S.C.; Lichinitser, M.; Lobo, C.; Maintz, C.; Maneecahvakajorn, J.; Marm{\'e}, A.; Martinez, G.; Masuda, N.; Matwiejuk, M.; Merculov, V.; Michaelson, R.; Miguel, L.; Monroy, H.; Montemurro, F.; Morales, S.; Moura, R.; Mueller, V.; Mulatero, C.; Nakagami, K.; Nakayama, T.; Neidhart, J.; Nguyen, A.; Nishimura, R.; Ogata, H.; O{'}reilly, S.; O{'}rourke, T.; Otero Reye, D.; Ouyang, X.; Patel, R.; Patel, T.; Pedrini, J.L.; Pereira, R.; Perez, A.; Peterson, C.; Pienkowski, T.; Pinczowski, H.; Polikoff, J.; Polkowski, W.; Price, P.E.; Prill, S.; Priou, F.; Purkalne, G.; Pyrhoenen, S.; Quackenbush, R.; Rai, Y.; Ribelles, N.; Ro, J.; Robinson, A.; Robles, R.; Rodriguez, G.; Roman, L.; Saji, S.; Sanchez-Rovira, P.; Sato, N.; Schmidt, M.; Schumacher, C.; Senecal, F.; Sharma, P.; Shen, Z.; Shirinkin, V.; Simoncini, E.; Sirisinha, T.; Smith, R.; Sohn, J.-H.; Soldic, Z.; Soria, T.; Spicer, D.; Srimuninnimit, V.; Sriuranpong, V.; Staroslawska, E.; Stefanovski, P.; Sunpaweravong, P.; Taguchi, J.; Takeda, K.; Tellez-Trevilla, G.; Thomas, R.; Thomssen, C.; Toache, Z.; Tokuda, Y.; Tomczak, P.; Tosello, C.; Tsugawa, K.; Tudtud, D.; Ueno, T.; Van Eyll, B.; Varela, M.; Vasev, N.; Vrbanec, D.; Wang, X.; Wang, L.; Watanabe, J.; Waterhouse, D.; Wesenberg, B.; Wheatley, D.; Wong, Z.W.; Yadav, S.; Yardley, D.; Yau, T.-K.; Yeo, W.; Ying, C.; Youn Oh, D.

  The Lancet Oncology, 2020

  
• Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.

  Takashi Hojo; Norikazu Masuda; Takayuki Iwamoto; Naoki Niikura; Keisei Anan; Kenjiro Aogi; Tatsuya Ohnishi; Chisako Yamauchi; Masayuki Yoshida; Takayuki Kinoshita; Hideji Masuoka; Yasuaki Sagara; Takashi Sakatani; Yasuyuki Kojima; Hitoshi Tsuda; Hiraku Kumamaru; Hiroaki Miyata; Seigo Nakamura

  Breast cancer (Tokyo, Japan), Jan. 2020

  
• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

  George W Sledge Jr; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Susana Barriga; Karla Hurt; Martin Frenzel; Stephen Johnston; Antonio Llombart-Cussac

  JAMA oncology, 01 Jan. 2020

  
• Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.

  Akira Matsui; Yuya Murata; Norikazu Masuda; Kiyoshi Mori; Masato Takahashi; Katsushige Yamashiro; Kenjirou Aogi; Shigeto Maeda; Masahiro Itou; Shinji Ozaki; Kazuya Kuraoka; Yasuyuki Satou; Shu Ichihara; Eriko Tokunaga; Kenichi Taguchi; Takanori Watanabe; Hiroyoshi Suzuki; Aiko Nagayama; Rieko Nishimura

  Oncotarget, 01 Oct. 2019

  
• Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.

  Akihiko Shimomura; Kan Yonemori; Masayuki Yoshida; Teruhiko Yoshida; Hiroyuki Yasojima; Norikazu Masuda; Kenjiro Aogi; Masato Takahashi; Yoichi Naito; Satoru Shimizu; Rikiya Nakamura; Akinobu Hamada; Hirofumi Michimae; Jun Hashimoto; Harukaze Yamamoto; Asuka Kawachi; Chikako Shimizu; Yasuhiro Fujiwara; Kenji Tamura

  Translational oncology, Oct. 2019

  
• Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.

  Mark Robson; Kathryn J Ruddy; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Wei Li; Nadine Tung; Anne Armstrong; Suzette Delaloge; Wendy Bannister; Carsten Goessl; Arnold Degboe; Robert Hettle; Pierfranco Conte

  European journal of cancer (Oxford, England : 1990), Oct. 2019

  
• Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.

  Takayuki Iwamoto; Naoki Niikura; Rin Ogiya; Hiroyuki Yasojima; Ken-Ichi Watanabe; Chizuko Kanbayashi; Michiko Tsuneizumi; Akira Matsui; Tomomi Fujisawa; Tsutomu Iwasa; Tadahiko Shien; Shigehira Saji; Norikazu Masuda; Hiroji Iwata

  Scientific reports, 16 Sep. 2019

  
• Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

  Norikazu Masuda; Hirofumi Mukai; Kenichi Inoue; Yoshiaki Rai; Shinji Ohno; Yuko Mori; Satoshi Hashigaki; Yasuaki Muramatsu; Yoshiko Umeyama; Hiroji Iwata; Masakazu Toi

  Breast cancer (Tokyo, Japan), Sep. 2019

  
• Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

  Nobuaki Sato; Norikazu Masuda; Takashi Morimoto; Takayuki Ueno; Chizuko Kanbayashi; Koji Kaneko; Hiroyuki Yasojima; Shigehira Saji; Hironobu Sasano; Satoshi Morita; Shinji Ohno; Masakazu Toi

  Cancer medicine, Sep. 2019

  
• Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

  Norikazu Masuda; Hirofumi Mukai; Kenichi Inoue; Yoshiaki Rai; Shinji Ohno; Yuko Mori; Satoshi Hashigaki; Yasuaki Muramatsu; Yoshiko Umeyama; Hiroji Iwata; Masakazu Toi

  Breast cancer (Tokyo, Japan), Sep. 2019

  
• Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

  Hiroji Iwata; Norikazu Masuda; Sung-Bae Kim; Kenichi Inoue; Yoshiaki Rai; Takashi Fujita; Joanne Chiu; Shoichiro Ohtani; Masato Takahashi; Toshiko Miyaki; Yen-Shen Lu; Binghe Xu; Yoon Sim Yap; Anita Bustam; Bin Yao; Bo Zhang; Richard Bryce; Arlene Chan

  Future oncology (London, England), Jul. 2019

  
• Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.

  Seock-Ah Im; Hirofumi Mukai; In Hae Park; Norikazu Masuda; Chikako Shimizu; Sung-Bae Kim; Young-Hyuck Im; Shoichiro Ohtani; Cynthia Huang Bartlett; Dongrui R Lu; Shrividya Iyer; Yuko Mori; Ave Mori; Eric Gauthier; Richard S Finn; Masakazu Toi

  Journal of global oncology, May 2019

  
• A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

  Kan Yonemori; Akihiko Shimomura; Hiroyuki Yasojima; Norikazu Masuda; Kenjiro Aogi; Masato Takahashi; Yoichi Naito; Satoru Shimizu; Rikiya Nakamura; Jun Hashimoto; Harukaze Yamamoto; Akihiro Hirakawa; Hirofumi Michimae; Akinobu Hamada; Teruhiko Yoshida; Tamie Sukigara; Kenji Tamura; Yasuhiro Fujiwara

  European journal of cancer (Oxford, England : 1990), Mar. 2019

  
• Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.

  Norikazu Masuda; Kenichi Inoue; Rikiya Nakamura; Yoshiaki Rai; Hirofumi Mukai; Shinji Ohno; Fumikata Hara; Yuko Mori; Satoshi Hashigaki; Yasuaki Muramatsu; Takashi Nagasawa; Yoshiko Umeyama; Xin Huang; Hiroji Iwata

  International journal of clinical oncology, Mar. 2019

  
• Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.

  Hirofumi Mukai; Chikako Shimizu; Norikazu Masuda; Shoichiro Ohtani; Shinji Ohno; Masato Takahashi; Yutaka Yamamoto; Reiki Nishimura; Nobuaki Sato; Shozo Ohsumi; Hiroji Iwata; Yuko Mori; Satoshi Hashigaki; Yasuaki Muramatsu; Takashi Nagasawa; Yoshiko Umeyama; Dongrui R Lu; Masakazu Toi

  International journal of clinical oncology, Mar. 2019

  
• Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR.

  Takayuki Ueno; Norikazu Masuda; Shunji Kamigaki; Takashi Morimoto; Shigehira Saji; Shigeru Imoto; Hironobu Sasano; Masakazu Toi

  International journal of molecular sciences, 24 Feb. 2019

  
• Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

  Yuichiro Miyoshi; Tadahiko Shien; Akiko Ogiya; Naoko Ishida; Kieko Yamazaki; Rie Horii; Yoshiya Horimoto; Norikazu Masuda; Hiroyuki Yasojima; Touko Inao; Tomofumi Osako; Masato Takahashi; Nobumoto Tomioka; Yumi Wanifuchi-Endo; Mitsuchika Hosoda; Hiroyoshi Doihara; Hiroko Yamashita

  Oncology letters, Feb. 2019

  
• Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.

  Hiroji Iwata; Norikazu Masuda; Yutaka Yamamoto; Tomomi Fujisawa; Tatsuya Toyama; Masahiro Kashiwaba; Shoichiro Ohtani; Naruto Taira; Takehiko Sakai; Yoshie Hasegawa; Rikiya Nakamura; Hiromitsu Akabane; Yukiko Shibahara; Hironobu Sasano; Takuhiro Yamaguchi; Kentaro Sakamaki; Helen Bailey; Diana B Cherbavaz; Debbie M Jakubowski; Naoko Sugiyama; Calvin Chao; Yasuo Ohashi

  Breast cancer research and treatment, 15 Jan. 2019

  
• OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

  Robson, M.E.; Tung, N.; Conte, P.; Im, S.-A.; Senkus, E.; Xu, B.; Masuda, N.; Delaloge, S.; Li, W.; Armstrong, A.; Wu, W.; Goessl, C.; Runswick, S.; Domchek, S.M.

  Annals of Oncology, 2019

  
• Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

  Takayuki Ueno; Shigehira Saji; Norikazu Masuda; Hiroji Iwata; Katsumasa Kuroi; Nobuaki Sato; Hiroyuki Takei; Yutaka Yamamoto; Shinji Ohno; Hiroko Yamashita; Kazufumi Hisamatsu; Kenjiro Aogi; Hironobu Sasano; Masakazu Toi

  ESMO open, 2019

  
• Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

  Masahiro Takada; Masahiro Sugimoto; Norikazu Masuda; Hiroji Iwata; Katsumasa Kuroi; Hiroyasu Yamashiro; Shinji Ohno; Hiroshi Ishiguro; Takashi Inamoto; Masakazu Toi

  Breast cancer research and treatment, Dec. 2018

  
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

  Nicholas C Turner; Dennis J Slamon; Jungsil Ro; Igor Bondarenko; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Sibylle Loibl; Fabrice André; Kathy Puyana Theall; Xin Huang; Carla Giorgetti; Cynthia Huang Bartlett; Massimo Cristofanilli

  The New England journal of medicine, 15 Nov. 2018

  
• Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

  Mario Campone; Seock-Ah Im; Hiroji Iwata; Mark Clemons; Yoshinori Ito; Ahmad Awada; Stephen Chia; Agnieszka Jagiełło-Gruszfeld; Barbara Pistilli; Ling-Ming Tseng; Sara Hurvitz; Norikazu Masuda; Javier Cortés; Michele De Laurentiis; Carlos L Arteaga; Zefei Jiang; Walter Jonat; Sylvie Le Mouhaër; Banu Sankaran; Laurence Bourdeau; Mona El-Hashimy; Dalila Sellami; José Baselga

  European journal of cancer (Oxford, England : 1990), Nov. 2018

  
• Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

  Massimo Cristofanilli; Angela DeMichele; Carla Giorgetti; Nicholas C Turner; Dennis J Slamon; Seock-Ah Im; Norikazu Masuda; Shailendra Verma; Sherene Loi; Marco Colleoni; Kathy Puyana Theall; Xin Huang; Yuan Liu; Cynthia Huang Bartlett

  European journal of cancer (Oxford, England : 1990), Nov. 2018

  
• A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

  Yutaka Yamamoto; Hiroji Iwata; Takayuki Ueno; Naruto Taira; Masahiro Kashiwaba; Masato Takahashi; Hiroshi Tada; Koichiro Tsugawa; Tatsuya Toyama; Naoki Niikura; Fumikata Hara; Tomomi Fujisawa; Tetsuhiro Yoshinami; Shigehira Saji; Toshimi Takano; Norikazu Masuda; Satoshi Morita; Masakazu Toi; Shinji Ohno

  Japanese journal of clinical oncology, 01 Sep. 2018

  
• Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

  Hope S Rugo; Nicholas C Turner; Richard S Finn; Anil A Joy; Sunil Verma; Nadia Harbeck; Norikazu Masuda; Seock-Ah Im; Xin Huang; Sindy Kim; Wan Sun; Shrividya Iyer; Patrick Schnell; Cynthia Huang Bartlett; Stephen Johnston

  European journal of cancer (Oxford, England : 1990), Sep. 2018

  
• Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).

  Shoichiro Ohtani; Takahiro Nakayama; Tetsuhiro Yoshinami; Ken-Ichi Watanabe; Fumikata Hara; Yasuaki Sagara; Hidetoshi Kawaguchi; Kenji Higaki; Nobuki Matsunami; Yoshie Hasegawa; Masato Takahashi; Makiko Mizutani; Takashi Morimoto; Masako Sato; Mitsuya Itoh; Satoshi Morita; Norikazu Masuda

  Breast cancer (Tokyo, Japan), Jul. 2018

  Access this paper :

  
• Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

  Nobuaki Sato; Norikazu Masuda; Takashi Morimoto; Takayuki Ueno; Chizuko Kanbayashi; Koji Kaneko; Hiroyuki Yasojima; Shigehira Saji; Hironobu Sasano; Satoshi Morita; Shinji Ohno; Masakazu Toi

  Cancer medicine, 14 Jun. 2018

  Access this paper :

  
• A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.

  Takayuki Ueno; Norikazu Masuda; Shunji Kamigaki; Takashi Morimoto; Futoshi Akiyama; Masafumi Kurosumi; Hitoshi Tsuda; Yoshiki Mikami; Sunao Tanaka; Satoshi Morita; Masakazu Toi

  Cancer medicine, Jun. 2018

  Access this paper :

  
• Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

  Ken Yoshida; Yuki Otani; Takayuki Nose; Eisaku Yoden; Shuuji Asahi; Iwao Tsukiyama; Takushi Dokiya; Toshiaki Saeki; Ichirou Fukuda; Hiroshi Sekine; Yu Kumazaki; Takao Takahashi; Tadayuki Kotsuma; Norikazu Masuda; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi

  Journal of contemporary brachytherapy, Jun. 2018

  
• Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.

  Tomoharu Sugie; Eiji Suzuki; Akira Yamauchi; Kazuhiko Yamagami; Norikazu Masuda; Naomi Gondo; Eriko Sumi; Takafumi Ikeda; Harue Tada; Ryuji Uozumi; Shotaro Kanao; Yoshimasa Tanaka; Yoko Hamazaki; Nagahiro Minato; Masakazu Toi

  Breast (Edinburgh, Scotland), Apr. 2018

  
• Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).

  Takahiro Nakayama; Yasuaki Sagara; Tsutomu Takashima; Nobuki Matsunami; Norikazu Masuda; Yasuo Miyoshi; Tetsuya Taguchi; Toyokazu Aono; Toshikazu Ito; Tatsuo Kagimura; Shinzaburo Noguchi

  Cancer chemotherapy and pharmacology, Apr. 2018

  
• Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.

  Norikazu Masuda; Reiki Nishimura; Masato Takahashi; Kenichi Inoue; Shinji Ohno; Hiroji Iwata; Yuko Mori; Satoshi Hashigaki; Yasuaki Muramatsu; Takashi Nagasawa; Yoshiko Umeyama; Masakazu Toi

  Cancer science, Mar. 2018

  Access this paper :

  
• Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

  Colleoni, M.; Luo, W.; Karlsson, P.; Chirgwin, J.; Aebi, S.; Jerusalem, G.; Neven, P.; Hitre, E.; Graas, M.-P.; Simoncini, E.; Kamby, C.; Thompson, A.; Loibl, S.; Gavil{\'a}, J.; Kuroi, K.; Marth, C.; M{\"u}ller, B.; O{'}Reilly, S.; Di Lauro, V.; Gombos, A.; Ruhstaller, T.; Burstein, H.; Ribi, K.; Bernhard, J.; Viale, G.; Maibach, R.; Rabaglio-Poretti, M.; Gelber, R.D.; Coates, A.S.; Di Leo, A.; Regan, M.M.; Goldhirsch, A.; Vandebroek, A.; Berliere, M.; Mitine, C.; Vuylsteke, P.; Borms, M.; D{'}Hondt, R.; Glorieux, P.; Mebis, J.; Verhoeven, D.; Coibion, M.; Forget, F.; Duck, L.; Verhoeven, D.; Wyendaele, W.; Barbeaux, A.; Salmon, J.-P.; Berteloot, P.; Vermeij, J.; Richard, V.; Cinieri, S.; Gianni, L.; Clerico, M.; Pinotti, G.; Bernardo, A.; Biganzoli, L.; Gennari, A.; Graiff, C.; Amadori, D.; Passalacqua, R.; Forbes, J.; Francis, P.; Foo, S.; Boyle, F.; Redfern, A.; van der Westhuizen, A.; Lewis, C.; Sharma, S.; Beale, P.; Byard, I.; Begbie, S.; Sardelic, F.; Abdi, E.; Clark, D.; Chindewere, A.; Della-Fiorentina, S.; Asghari, R.; Islam, M.; Na Teo, L.; White, S.; Gilbert, L.; Gardner, K.; Uhlmann, C.; Rauch, D.; Mannhart, M.; Buser, K.; Dedes, K.; Mueller, A.; Rageth, C.; Von Orelli, S.; Senn, H.J.; Pagani, O.; Pedrazzini, A.; Rochlitz, C.; Bodmer, A.; Anchisi, S.; Zaman, K.; von Moos, R.; Betticher, D.; Kralidas, E.; Popescu, R.; Fehr, M.; Nyman, P.; Jungquist, A.; Chamalidou, C.; Foukakis, T.; Dabrosin, C.; Valachis, A.; Lang, I.; Kahan, Z.; Retamales, J.; Torres, U.R.; Fritis, M.; Sole, S.; Torres, S.; Letzkus, J.; Escobar, P.; Vigneaux, I.; Arancibia, J.; Cardemil, J.B.; Huidobro, P.; Gomez, H.; Wetter, J.; Vorobiof, D.; McMichael, G.; Apffelstaedt, J.; Vorotnikov, I.; Schwartz, J.; Openshaw, T.; Bonnefoi, H.; Jacquin, J.-P.; Bonichon-Lamichhane, N.; Borstner, S.; Budrukkar, A.; Ewertz, M.; Quispe, O.Z.; Vestlev, P.M.; Dan?, H.; Nielsen, D.; Jakobsen, E.; Hoejris, I.; Bogovic, J.A.; Jensen, B.B.; Aage M?ller, K.; Stenbygaard, E.L.; Sharma, R.; Bedi, C.; Bews-Hair, M.; Neades, G.; McKirdy, M.; Barber, M.; Alhasso, A.; Ritchie, D.; Fraser, J.; Scott, L.; Yuille, F.; Lannigan, A.; Murphy, D.; Shere, M.; Jackisch, C.; Tom{\'e}, O.; Steer, S.; Augustin, D.; u}bbe, K.; Jackisch, C.; K{\"o}cker-Korus, H.; Deuker, J.-U.; Stefek, A.; Just, M.; Rhein, U.; Bechtner, C.; Baerens, D.-T.; Schrader, I.; Grischke, E.-M.; Lorenz, R.; Dietz, W.; Thomalla, J.; Schilling, J.; Rempen, A.; Graf, H.; Doering, G.; Busch, S.; Heinrich, G.; Tesch, H.; Uleer, C.; Krabisch, P.; R{\"o}sel, S.; Kurbacher, C.; Ostertag, H.; Josten, K.-M.; Hielscher, C.; Gr{\"o}ll, I.; Mattner, U.M.; Prechtl, A.; Lantzsch, T.; Ciruelos, E.; Garau, I.; Bellet, M.; Climent, M.A.; L{\'o}pez, R.; Virizuela, J.A.; Bermejo, B.; Janez, N.M.; Amillano, K.; M{\'a}rquez, R.; Dorca, J.; Godes, M.J.; Gonzalez, S.; Ohno, S.; Aruga, T.; Yotsumoto, D.; Yamamoto, Y.; Aihara, T.; Morimoto, T.; Bando, H.; Masuda, N.; Toi, M.; Aogi, K.; Sato, N.; Okada, M.; Takahashi, M.; Tokunaga, E.; Iwata, H.; Fujita, T.; Fridrik, M.; Pristauz, G.; Hackl, C.; Singer, C.; Wette, V.; Gnant, M.; Thaler, J.; Greil, R.; Abendstein, B.; Heck, D.; Manfreda, D.; Sevelda, P.; Thiel, I.; Tuttlies, F.; St{\"o}ger, H.; Neunteufel, W.; Crown, J.; Kennedy, J.; Hill, A.; McCaffrey, J.; Murphy, C.; Coate, L.; Keane, M.; Martin, M.; O{'}Connor, M.; Duffy, K.; Ruepp, B.; Piccart, M.; Zardavas, D.

  The Lancet Oncology, 2018

  
• Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

  Masuda, N.; Toi, M.; Yamamoto, N.; Iwata, H.; Kuroi, K.; Bando, H.; Ohtani, S.; Takano, T.; Inoue, K.; Yanagita, Y.; Kasai, H.; Morita, S.; Sakurai, T.; Ohno, S.

  Breast Cancer, 2018

  Access this paper :

  
• Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.

  Masaya Hattori; Hiroshi Ishiguro; Norikazu Masuda; Akiyo Yoshimura; Shoichiro Ohtani; Hiroyuki Yasojima; Satoshi Morita; Shinji Ohno; Hiroji Iwata

  Breast cancer (Tokyo, Japan), Jan. 2018

  
• Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

  Naoki Niikura; Akihiko Shimomura; Yumi Fukatsu; Masataka Sawaki; Rin Ogiya; Hiroyuki Yasojima; Tomomi Fujisawa; Mitsugu Yamamoto; Michiko Tsuneizumi; Akira Kitani; Junichiro Watanabe; Akira Matsui; Yuko Takahashi; Seiki Takashima; Tadatoshi Shien; Kenji Tamura; Shigehira Saji; Norikazu Masuda; Yutaka Tokuda; Hhiroji Iwata

  Breast cancer research and treatment, Jan. 2018

  
• Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.

  Hidetoshi Kawaguchi; Norikazu Masuda; Takahiro Nakayama; Kenjiro Aogi; Keisei Anan; Yoshinori Ito; Shoichiro Ohtani; Nobuaki Sato; Shigehira Saji; Toshimi Takano; Eriko Tokunaga; Seigo Nakamura; Yoshie Hasegawa; Masaya Hattori; Tomomi Fujisawa; Satoshi Morita; Miki Yamaguchi; Hiroko Yamashita; Toshinari Yamashita; Yutaka Yamamoto; Daisuke Yotsumoto; Masakazu Toi; Shinji Ohno

  Current medical research and opinion, Jan. 2018

  
• Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

  Takayuki Ueno; Shigehira Saji; Norikazu Masuda; Katsumasa Kuroi; Nobuaki Sato; Hiroyuki Takei; Yutaka Yamamoto; Shinji Ohno; Hiroko Yamashita; Kazufumi Hisamatsu; Kenjiro Aogi; Hiroji Iwata; Takeharu Yamanaka; Hironobu Sasano; Masakazu Toi

  ESMO open, 2018

  
• Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

  Niwa H; Otani S; Nakada N; Sasaki J; Saka H; Masuda N

  Respiratory Medicine Case Reports, 2018

  
• Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.

  Masaya Hattori; Hiroshi Ishiguro; Norikazu Masuda; Akiyo Yoshimura; Shoichiro Ohtani; Hiroyuki Yasojima; Satoshi Morita; Shinji Ohno; Hiroji Iwata

  Breast cancer (Tokyo, Japan), Jan. 2018

  
• Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.

  Hiroyasu Yamashiro; Masataka Sawaki; Norikazu Masuda; Yasuhiro Okumura; Toshimi Takano; Eriko Tokunaga; Tsuyoshi Saito; Yasuaki Sagara; Kosuke Yamazaki; Yoshihiro Kawaguchi; Tecchuu Lee; Shinji Ozaki; Kazuhiko Yamagami; Naohito Yamamoto; Katsumasa Kuroi; Hirofumi Suwa; Shoichiro Ohtani; Toshikazu Ito; Shinji Yasuno; Satoshi Morita; Shinji Ohno; Masakazu Toi

  Breast cancer : basic and clinical research, 2018

  
• Capecitabine for primary breast cancer.

  Masakazu Toi; Norikazu Masuda; Soo-Jung Lee

  Oncotarget, 19 Dec. 2017

  
• Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

  Rin Ogiya; Naoki Niikura; Nobue Kumaki; Hiroyuki Yasojima; Tsutomu Iwasa; Chizuko Kanbayashi; Risa Oshitanai; Michiko Tsuneizumi; Ken-Ichi Watanabe; Akira Matsui; Tomomi Fujisawa; Shigehira Saji; Norikazu Masuda; Yutaka Tokuda; Hiroji Iwata

  Oncotarget, 28 Nov. 2017

  
• MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

  George W Sledge Jr; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; Martin Frenzel; Yong Lin; Susana Barriga; Ian C Smith; Nawel Bourayou; Antonio Llombart-Cussac

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 Sep. 2017

  
• Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

  Sibylle Loibl; Nicholas C Turner; Jungsil Ro; Massimo Cristofanilli; Hiroji Iwata; Seock-Ah Im; Norikazu Masuda; Sherene Loi; Fabrice André; Nadia Harbeck; Sunil Verma; Elizabeth Folkerd; Kathy Puyana Theall; Justin Hoffman; Ke Zhang; Cynthia Huang Bartlett; Mitchell Dowsett

  The oncologist, Sep. 2017

  
• Adjuvant Capecitabine for Breast Cancer.

  Masakazu Toi; Norikazu Masuda; Yasuo Ohashi

  The New England journal of medicine, 24 Aug. 2017

  
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte

  The New England journal of medicine, 10 Aug. 2017

  
• PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

  Hiroji Iwata; Seock-Ah Im; Norikazu Masuda; Young-Hyuck Im; Kenichi Inoue; Yoshiaki Rai; Rikiya Nakamura; Jee Hyun Kim; Justin T Hoffman; Ke Zhang; Carla Giorgetti; Shrividya Iyer; Patrick T Schnell; Cynthia Huang Bartlett; Jungsil Ro

  Journal of global oncology, Aug. 2017

  
• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  José Baselga; Seock-Ah Im; Hiroji Iwata; Javier Cortés; Michele De Laurentiis; Zefei Jiang; Carlos L Arteaga; Walter Jonat; Mark Clemons; Yoshinori Ito; Ahmad Awada; Stephen Chia; Agnieszka Jagiełło-Gruszfeld; Barbara Pistilli; Ling-Ming Tseng; Sara Hurvitz; Norikazu Masuda; Masato Takahashi; Peter Vuylsteke; Soulef Hachemi; Bharani Dharan; Emmanuelle Di Tomaso; Patrick Urban; Cristian Massacesi; Mario Campone

  The Lancet. Oncology, Jul. 2017

  
• Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.

  Akiko Ogiya; Kieko Yamazaki; Rie Horii; Tadahiko Shien; Yoshiya Horimoto; Norikazu Masuda; Touko Inao; Mitsuchika Hosoda; Naoko Ishida; Tomofumi Osako; Masato Takahashi; Yumi Endo; Yuichiro Miyoshi; Hiroyuki Yasojima; Nobumoto Tomioka; Hiroko Yamashita

  Breast cancer (Tokyo, Japan), 01 Jul. 2017

  
• Uncertainty of cosmetic evaluation after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

  Eisaku Yoden; Takayuki Nose; Yuki Otani; Shuuji Asahi; Iwao Tsukiyama; Takushi Dokiya; Toshiaki Saeki; Ichirou Fukuda; Hiroshi Sekine; Naoto Shikama; Yu Kumazaki; Takao Takahashi; Ken Yoshida; Tadayuki Kotsuma; Norikazu Masuda; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi

  Japanese journal of radiology, Jul. 2017

  
• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

  Norikazu Masuda; Soo-Jung Lee; Shoichiro Ohtani; Young-Hyuck Im; Eun-Sook Lee; Isao Yokota; Katsumasa Kuroi; Seock-Ah Im; Byeong-Woo Park; Sung-Bae Kim; Yasuhiro Yanagita; Shinji Ohno; Shintaro Takao; Kenjiro Aogi; Hiroji Iwata; Joon Jeong; Aeree Kim; Kyong-Hwa Park; Hironobu Sasano; Yasuo Ohashi; Masakazu Toi

  The New England journal of medicine, 01 Jun. 2017

  
• Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.

  Kiyoshi Mori; Masashi Takeda; Yoshinori Kodama; Hiroki Kiyokawa; Hiroyuki Yasojima; Makiko Mizutani; Yoko Otani; Nozomi Morikawa; Norikazu Masuda; Masayuki Mano

  Human pathology, Jun. 2017

  
• Widespread subdural metastasis from breast cancer progressing rapidly with cerebral herniation: A case report.

  Yoshiko Okita; Norikazu Masuda; Makiko Mizutani; Yoshinori Kodama; Kiyoshi Mori; Masayuki Mano; Tomoyoshi Nakagawa; Shin Nakajima; Toshiyuki Fujinaka

  Molecular and clinical oncology, Jun. 2017

  
• First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.

  Norikazu Masuda; Masato Takahashi; Kazuhiko Nakagami; Yasuhiro Okumura; Takahiro Nakayama; Nobuaki Sato; Kazumitsu Kanatani; Kosei Tajima; Masahiro Kashiwaba

  Japanese journal of clinical oncology, 01 May 2017

  
• Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.

  Akiko Ogiya; Kieko Yamazaki; Rie Horii; Tadahiko Shien; Yoshiya Horimoto; Norikazu Masuda; Touko Inao; Mitsuchika Hosoda; Naoko Ishida; Tomofumi Osako; Masato Takahashi; Yumi Endo; Yuichiro Miyoshi; Hiroyuki Yasojima; Nobumoto Tomioka; Hiroko Yamashita

  Breast cancer (Tokyo, Japan), 01 May 2017

  
• Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

  Kenji Tamura; Kenichi Inoue; Norikazu Masuda; Shintaro Takao; Masahiro Kashiwaba; Yutaka Tokuda; Hiroji Iwata; Naohito Yamamoto; Kenjiro Aogi; Toshiaki Saeki; Takahiro Nakayama; Nobuaki Sato; Tatsuya Toyama; Takanori Ishida; Hitoshi Arioka; Mitsue Saito; Shinji Ohno; Hideko Yamauchi; Kimito Yamada; Junichiro Watanabe; Hiroshi Ishiguro; Yasuhiro Fujiwara

  Cancer science, May 2017

  Access this paper :

  
• Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.

  Junichiro Watanabe; Yoshinori Ito; Toshiaki Saeki; Norikazu Masuda; Toshimi Takano; Shintaro Takao; Kazuhiko Nakagami; Koichiro Tsugawa; Shintaro Nakagawa; Kazumitsu Kanatani; Takahiro Nakayama

  In vivo (Athens, Greece), May 2017

  
• Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.

  Hiroji Iwata; Norikazu Masuda; Daigo Yamamoto; Yoshiaki Sagara; Nobuaki Sato; Yutaka Yamamoto; Mitsue Saito; Takashi Fujita; Shoji Oura; Junichiro Watanabe; Masami Tsukabe; Kazumi Horiguchi; Satoshi Hattori; Yoshimasa Matsuura; Katsumasa Kuroi

  Breast cancer research and treatment, Apr. 2017

  
• Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.

  Toru Watanabe; Masaru Kuranami; Kenichi Inoue; Norikazu Masuda; Kenjiro Aogi; Shinji Ohno; Hiroji Iwata; Hirofumi Mukai; Yukari Uemura; Yasuo Ohashi

  Cancer, 01 Mar. 2017

  
• Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence.

  Tadahiko Shien; Takehiro Tanaka; Masahiko Tanabe; Yasuhiro Okumura; Norikazu Masuda; Atsushi Yoshida; Nobuyuki Arima; Yoshifumi Komoike; Satoru Tanaka; Takuji Iwase; Tetsuya Taguchi; Katsuhiko Nakatsukasa; Hideo Inaji; Makoto Ishitobi

  Oncology letters, Mar. 2017

  
• A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer

  Yoshioka H; Katakami N; Okamoto H; Iwamoto Y; Seto T; Takahashi T; Sunaga N; Kudoh S; Chikamori K; Harada M; Tanaka H; Saito H; Saka H; Takeda K; Nogami N; Masuda N; Harada T; Kitagawa H; Horio H; Yamanaka T; Fukuoka M; Yamamoto N; Nakagawa K

  Annals of Oncology, Feb. 2017

  
• Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.

  Daigo Yamamoto; Nobuaki Sato; Yoshiaki Rai; Yutaka Yamamoto; Mitsue Saito; Hiroji Iwata; Norikazu Masuda; Shoji Oura; Junichiro Watanabe; Satoshi Hattori; Yoshimasa Matsuura; Katsumasa Kuroi

  Breast cancer research and treatment, Feb. 2017

  
• The authors reply

  Toi, M.; Masuda, N.; Ohashi, Y.

  New England Journal of Medicine, 2017

  
• Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

  Martin, M.; Holmes, F.A.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.K.L.; Mansi, J.; Barrios, C.H.; Gnant, M.; Toma?evi?, Z.; Denduluri, N.; eparovi?, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.-B.; Jakobsen, E.H.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.B.; Armstrong, A.C.; Link, J.S.; Joy, A.A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, A.; Harvey, V.; Tomek, R.; Robert, N.J.; Gore, I.; Smith, J.W.; Masuda, N.; Di Sean Kendall, S.; Harker, W.G.; Petrakova, K.; Guerrero Zotano, A.; Simon, A.R.; Konstantinovic, Z.N.; Iannotti, N.O.; Tassone, P.; Rodriguez, G.I.; J{\'a; n}ez; Martinez, N.; Crespo Massieu, C.; Smickoska, S.; Somali, I.; Yilmaz, U.; Alonso, M.G.; Rosales, A.M.; Cold, S.; Knoop, A.S.; Patt, D.; Hellerstedt, B.A.; Morales Murillo, S.; Mayer, I.A.; Means-Powell, J.A.; Hui, R.; Senecal, F.M.; De Boer, R.H.; Shen, Z.; Luczak, A.A.; Chui, J.W.Y.; Tsang, J.W.-H.; Lang, I.; Rai, Y.; Hozumi, Y.; Ten Tije, A.J.; Bhandari, M.; Osborne, C.R.C.; Ohtani, S.; Higaki, K.; Watanabe, K.; Taguchi, K.; Takahashi, M.; Filipovic, S.; Hansen, V.L.; Rao, V.P.; Gupta, M.; Petrov, P.; Coudert, B.; Vojnovic, Z.; Polya, Z.; Miyaki, T.; Yamamoto, N.; Brincat, S.; Lesniewski-Kmak, K.; Chmielowska, E.; Birhiray, R.E.; Citron, M.L.; Papish, S.W.; Berry, W.R.; Langkjer, S.T.; Garcia S{\'a}enz, J.A.; Arance, A.M.; Efrat, N.; Sarosiek, T.; Grzeda, L.; Manalo, Y.; Smith, J.C.; Vaziri, I.; Healey, T.; Rahim, Y.; Luk, C.; Dingle, B.; Franco, S.; Sorensen, P.G.; Anand, A.; Khan, S.; Fountzilas, G.; Aogi, K.; Shimizu, S.; Mikulova, M.; Spanik, S.; Somer, R.A.; Flynn, P.J.; Coward, J.; Mainwaring, P.; Jerusalem, G.; Segura-Ojezzar, C.; Levy, C.; Delozier, T.; Khayat, D.; Coleman, R.E.; Rolles, M.J.; Maisano, R.; Nardi, M.; Ito, Y.; Yumuk, P.F.; Basaran, G.; Serdar Turhal, N.; Wilkinson, M.J.; Green, N.B.; Sidrys, A.P.; Hallmeyer, S.; Testori, D.J.; Sridhar, S.; Chang, J.; Sun, Q.; Jara-Sanchez, C.; Rubio, X.; Garrido, M.L.; De La Haba Rodriguez, J.R.; Perello Martorell, A.; Avelia Mestre, A.; Rifa Ferrer, J.; del Barco Berron, S.; Nagy, Z.; Tanaka, M.; Im, Y.-H.; Carroll, R.R.; Dickerson, L.C.; Mace, J.R.; Rivera, R.; Klein, L.M.; Ruxer, R.; Wilks, S.T.; Kotasek, D.; Popov, V.; Taskova, V.; Marinova-Venkova, V.; Timcheva, C.; Desbiens, C.; Ayoub, J.-P.; Grenier, D.; Marschner, N.; Tesch, H.; Lueck, H.-J.; Janssen, J.; Schwaner, I.; Wahlstrom, S.; Brix, E.H.; Vallentin, S.; Kristensen, D.; Andreeva, A.; Glavicic, V.; Calvo Plaza, I.; Anton Torres, A.; Veyret, C.; Bergerat, J.-P.; Bourbouloux, E.; Ella, W.A.; Algurafi, H.; Robinson, A.; Kim, S.J.; Taguchi, T.; Juozaityte, E.; Madretsma, S.; Radema, S.; Czerniawska-Meier, M.; Rogowski, W.; Wagnerova, M.; Richards, D.A.; Tan-Chiu, E.; Vasileios, A.; Henderson, C.A.; Holden, V.R.; Wang, X.; Tong, Z.; Yang, J.; Gonzalez, M.E.; Rezai, M.; Hackmann, J.; de Due{\~n}as, E.M.; de las Heras, B.B.; Dourthe, L.M.; Chocteau-Bouju, D.; Bougnoux, P.; Kakolyris, S.; Kalofonos, H.; Pectasidis, D.; Ng, T.Y.; Pajkos, G.; Somogyine, E.E.; Tonini, G.; Giuffrida, D.; Takao, S.; Ishitobi, M.; Inaji, H.; Tokuda, Y.; Wozniak, K.; Lungulescu, D.; Lu, Y.-S.; Chang, K.-J.; Hill, J.; Croot, C.C.; Dekker, A.; Belman, N.D.; Conde, M.; Michaelson, R.A.; Kemmer, K.; Chui, S.; Luoh, S.-W.; Nahum, K.; Greenspan, A.R.; Nichols, J.C.; Encarnacion, C.A.; Niederman, T.M.J.; Lee, T.; Alexander, R.; Gordon, R.; Tomova, A.; Rauch, D.; Popescu, R.A.; Rojas, G.A.; Vanasek, J.; Neunhoeffer, T.; Barinoff, J.; Graffunder, G.; Wolfgang, A.; Bojko, P.; Heinrich, B.; von der Assen, A.; Antonovic, B.J.; Adrian, L.; Ramos Vazquez, M.; Gonzalez Santiago, S.; Dieras, V.; Bishop, J.M.; Perren, T.J.; Varthalitis, I.; Mavroudis, D.; Georgoulias, V.; d Chow; L.W.C.; d Yau; C.C.T.; Liang, R.H.-S.; Pik{\'o}, B.; W{\'e}ber, A.; Kaufman, B.; Drumea, K.; Nuzzo, F.; De Matteis, A.; Nuzzo, F.; Carteni, G.; Tokunaga, E.; Ishida, M.; Ohno, S.; Sato, N.; Kuroi, K.; Nishimura, R.; Watanabe, J.; Choi, Y.J.; Park, K.H.; Wojtukiewicz, M.; Jassem, J.; Loman, N.; Askoy, S.; Altundag, M.K.; Saip, P.; Ali, M.A.; Wade, J.L.; Chien, A.J.; Brandt, D.; Novik, Y.; Jani, C.; Rice, R.L.; Gaffar, Y.A.R.; Keaton, M.R.; Bajaj, R.; Kimmick, G.; Campbell, D.; De Boer, R.H.; Turnquest, T.; Lucas, S.; Dube, P.; Xu, B.; Schilling, J.; Apel, K.; Sorensen, P.G.; Vestlev, P.M.; Jensen, B.B.; Haahr, V.; Lescure, A.R.; Grana Suarez, B.; Saura Manich, C.; Jacquin, J.-P.; Samreen, A.; Boiangiu, I.; Dank, M.; Falci, C.; Jirillo, A.; Cinieri, S.; Ueno, T.; Sato, F.; Yamashiro, H.; Sugie, T.; Lee, K.S.; Ro, J.S.; Park, I.H.; Bustam, A.Z.; Suszko-Kazarnowicz, M.; Piktel, A.; Krzemieniecki, K.; Iorga, P.G.; Yap, Y.S.; Kakalejcik, M.; Sevinc, A.; Ozguroglu, M.; Chen, S.-C.; Greenberg, R.H.; Eisemann, A.D.; Droder, R.; Abbasi, M.R.; Vaysburd, M.; Caldera, H.J.; Haley, B.B.; Robin, E.; Inhorn, R.C.; Hufnagel, D.; Kenyon, P.D.; Spremulli, E.; Silverman, P.; Jain, S.; Weigand, R.; Mebis, J.; Koynova, T.; Lesperance, B.; Prausova, J.; Kohne, C.-H.; Schneeweiss, A.; Jackisch, C.; Fuxius, S.; Cubedo Cervera, R.; Urruticoechea Ribate, A.; Pernas Simon, S.; Valero Gallego, J.; Arcusa Lanza, A.; del Pilar Alvarez, M.; Florian Gerico, J.; Cany, L.; Stebbing, J.; Labudovic, D.; Gugic, D.; Vrbanec, D.; Roila, F.; Barni, S.; Bidoli, P.; Mukai, H.; Bermudez, V.; Eniu, A.; Mirtsching, B.C.; Ibrahim, E.; Trey, J.; Hergenroeder, P.F.; Mahmood, A.; Gonzalez, A.; Kaplan, E.H.; Ban, S.; Patel, D.; Clowney, B.; Hoelzer, K.; Schwartz, G.H.; Salkeni, M.; Abraham, J.; Narula, S.; Jabboury, K.; Mocharnuk, R.S.; McDonough, R.H.; Sikes, D.H.; Kawanchi, R.H.; Schlabach, L.; McCachren, S.S.; Cosgriff, T.M.; Dreisbach, L.; DeMichele, A.; Pawl, L.; Lucas, J.; Shinn, L.C.; Alkhouri, N.; Monga, M.; Lindquist, D.L.; Anderson, T.C.; Khurshid, H.; Witherby, S.; Erickson, N.; Traynor, A.; Bose, R.; Pluard, T.J.; Jones, M.C.; Prakash, S.; Volterra, F.; Capo, G.; Flaherty, L.E.; Gartner, E.; Baidas, S.; Okazaki, I.; Nguyen, B.; Rakowski, T.; Oliff, I.; Leach, J.W.; Anderson, D.; Kubiak, K.; Tsai, M.; Vroman, P.; Deleu, I.; Lybaert, W.; Borms, M.; Couture, F.; Wilson, J.J.; Hunt, G.; Holland, D.R.; Mingrone, W.; Wang, S.; Liu, D.; Jiang, Z.; Benesova, V.; Smakal, M.; Garnolova, P.; Vesper, A.-S.; Neumann, M.; Janni, W.; Liedtke, C.; Fischer, D.; Grischke, E.-M.; Seeger, D.; Moebus, V.; Prechtl, A.; Carlos Camara Toral, J.; Sanchez Munoz, A.; Gonzalez Jimenez, S.; Cassinello Espinosa, J.; Cirauqui, B.; Margeli Vila, M.; Batista Lopez, N.; Chacon Lopez-Muniz, J.I.; de la Cruz; Mora, M.A.; Mailliez, A.; Vanlemmens, L.; Pouessel, D.; Espie, M.; Conibear, J.; Roylance, R.; Harnett, A.; Geffen, D.; Ruggeri, E.M.; Gamucci, T.; Van Groeningen, C.J.; Banas, R.; Alkis, N.; Hou, M.-F.; Krie, A.K.; Vrindavanam, N.S.; Howard, O.M.; Citrin, D.; Morginstin, M.S.; Desai, A.; Sanchez, I.J.; Nixon, D.A.; Beatty, P.G.; Edmiston, K.; McLaughlin, M.; Eneman, J.D.; Lynch, C.A.; O{'}Brien, E.; Call, J.A.; Lanier, K.S.; Conlin, A.; Brooks, D.J.; McIntyre, K.; Saltzman, M.A.; Castine, M.J.; Ortega, G.L.; Choi, Y.M.; Reynolds, C.H.; Brescia, F.A.; Kramer, R.; Kohn, A.D.; Micha, J.P.; Rhee, J.M.; Shah, S.; Riseberg, D.A.; Patterson, W.K.; Salmon, J.-P.; Andre, C.; Bols, A.; D{'}hondt, R.; Luce, S.; Nouwynck, C.; Pelgrims, G.; Richard, V.; Verschuere, J.; Geldhof, K.; Caspar, C.; Luo, R.; Bednarik, O.; Schwedler, K.; Schmidt, M.; Neumeister, R.; Bischoff, J.; Rack, B.; Repp, R.; Fries, S.; Adrion, R.; Schulz, V.; Klare, P.; Danei, M.; Ossenbuhl, D.; Kusche, J.M.; Griesinger, F.; Baena Canada, J.M.; Martinez del; Prado, P.; Machover, D.; Mayeur, D.; Trufflandier, N.; Delecroix, V.; Mousseau, M.; Mouret-Reynier, M.-A.; Nabholtz, J.-M.; Chetiyawardana; A.D. and; Papa; dreou, C.; Hornyak, L.; Faluhelyi, Z.; Simo, E.; Di Palma, M.; Cognetti, F.; Gorzegno, G.; Dogliotti, L.; Gridelli, C.; Falcone, A.; Soto Parra, H.; Buscarino, C.; Im, S.-A.; Sanchez Llamas, B.; Dercksen, W.; Erdkamp, F.; Ruit, J.B.; Braun, H.; Portielje, J.E.A.; Ciltas, A.; Buyukberber, S.; Benekli, M.; Zahalsky, A.J.; Jaslow, R.; Thomas, G.W.; Maini, A.; Wiznitzer, I.; Khojasteh, A.; Francisco Gonzalez, M.; Kong, L.R.; Padmanabhan, A.; Conkright, W.A.; Swain, S.M.; Faig, D.E.; Jain, K.; Yanagihara, R.H.; Ottaviano, Y.; Delmas, A.; Steele, H.A.; Rainey, G.K.; Harris, P.J.; Burris, J.K.; Rupard, E.J.; Tan, E.; Whitworth, P.W.; Bova, A.R.; Anderson, I.C.; Shirinian, M.; Tin-u, C.; O{'}Rourke, T.J.; Roberts, M.S.; Francisco, M.; Pierson, A.S.; Byeff, P.D.; Kovach, P.A.; Caton, J.R.; Rarick, M.U.; Schimidt, W.G.; Stopeck, A.T.; Swart, R.; Carrillo Flores, M.R.; Alemany, C.A.; Lozada, B.; Weinstein, P.L.; Wang, W.; Porubcin, M.; Ellison, D.M.; Geils, G.F.; Rivera, E.; Charif, M.

  The Lancet Oncology, 2017

  
• Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triplenegative early breast cancer

  Bell, R.; Brown, J.; Parmar, M.; Toi, M.; Suter, T.; Steger, G.G.; Pivot, X.; Mackey, J.; Jackisch, C.; Dent, R.; Hall, P.; Xu, N.; Morales, L.; Provencher, L.; Hegg, R.; anlemmens, L.; Kirsch, A.; Schneeweiss, A.; Masuda, N.; Overkamp, F.; Cameron, D.

  Annals of Oncology, 2017

  
• Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

  Kawaguchi, H.; Masuda, N.; Nakayama, T.; Aogi, K.; Anan, K.; Ito, Y.; Ohtani, S.; Sato, N.; Saji, S.; Tokunaga, E.; Nakamura, S.; Hasegawa, Y.; Hattori, M.; Fujisawa, T.; Morita, S.; Yamaguchi, M.; Yamashita, T.; Yamamoto, Y.; Ohno, S.; Toi, M.

  Breast Cancer Research and Treatment, 2017

  
• Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

  Nakamura, K.; Okada, E.; Ukawa, S.; Hirata, M.; Nagai, A.; Yamagata, Z.; Kiyohara, Y.; Muto, K.; Kamatani, Y.; Ninomiya, T.; Matsuda, K.; Kubo, M.; Nakamura, Y.; Tamakoshi, A.; Shimoyama, R.; Maekawa, K.; Kaneko, K.; Harada, H.; Minami, S.; Takei, H.; Saito, M.; Terao, Y.; Takeda, S.; Asai, S.; Moriyama, M.; Takahashi, Y.; Fujioka, T.; Obara, W.; Mori, S.; Ito, H.; Nagayama, S.; Miki, Y.; Masumoto, A.; Yamada, A.; Nishizawa, Y.; Kodama, K.; Abe, H.; Shimizu, T.; Koretsune, Y.; Masuda, N.; Takeda, Y.

  Journal of Epidemiology, 2017

  
• Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer

  Ohgami, M.; Bando, H.; Ishiguro, H.; Tsuda, M.; Toriguchi, N.; Aogi, K.; Toi, M.; Masuda, N.; Mitsuhashi, S.; Kurosawa, A.; Homma, M.

  Annals of Oncology, 2017

  
• Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

  David Miles; David Cameron; Igor Bondarenko; Lyudmila Manzyuk; Juan Carlos Alcedo; Roberto Ivan Lopez; Seock-Ah Im; Jean-Luc Canon; Yaroslav Shparyk; Denise A Yardley; Norikazu Masuda; Jungsil Ro; Neelima Denduluri; Stanislas Hubeaux; Cheng Quah; Carlos Bais; Joyce O'Shaughnessy

  European journal of cancer (Oxford, England : 1990), Jan. 2017

  
• Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.

  Jun Yamamura; Norikazu Masuda; Daigo Yamamoto; Shigeru Tsuyuki; Masahide Yamaguchi; Satoru Tanaka; Junji Tsurutani; Shinya Tokunaga; Katsuhide Yoshidome; Makiko Mizutani; Toyokazu Aono; Asako Ooe; Hirokazu Tanino; Nobuki Matsunami; Hiroyuki Yasojima; Takahiro Nakayama; Yukihiro Nishida

  Chemotherapy, 2017

  
• Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.

  Norikazu Masuda; Hiroji Iwata; Kenjiro Aogi; Yihuan Xu; Ayman Ibrahim; Ling Gao; Rita Dalal; Reigetsu Yoshikawa; Yasutsuna Sasaki

  Japanese journal of clinical oncology, Dec. 2016

  
• [A Case of Recurrent Breast Cancer with Adrenal Metastasis Resected Using Laparoscopic Surgery].

  Hirotomo Murakami; Yoko Ohtani; Tatsuya Kinoshita; Kiyo Tanaka; Hiroyuki Yasojima; Makiko Mizutani; Shoji Nakamori; Mitsugu Sekimoto; Kiyoshi Mori; Masayuki Mano; Norikazu Masuda

  Gan to kagaku ryoho. Cancer & chemotherapy, Nov. 2016

  
• A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months.

  Takayuki Nose; Yuki Otani; Shuuji Asahi; Iwao Tsukiyama; Takushi Dokiya; Toshiaki Saeki; Ichirou Fukuda; Hiroshi Sekine; Naoto Shikama; Yu Kumazaki; Takao Takahashi; Ken Yoshida; Tadayuki Kotsuma; Norikazu Masuda; Eisaku Yoden; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi

  Breast cancer (Tokyo, Japan), Nov. 2016

  
• Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

  Hiroko Yamashita; Akiko Ogiya; Tadahiko Shien; Yoshiya Horimoto; Norikazu Masuda; Touko Inao; Tomofumi Osako; Masato Takahashi; Yumi Endo; Mitsuchika Hosoda; Naoko Ishida; Rie Horii; Kieko Yamazaki; Yuichiro Miyoshi; Hiroyuki Yasojima; Nobumoto Tomioka

  Breast cancer (Tokyo, Japan), 01 Nov. 2016

  
• Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.

  Yuichiro Miyoshi; Tadahiko Shien; Akiko Ogiya; Naoko Ishida; Kieko Yamazaki; Rie Horii; Yoshiya Horimoto; Norikazu Masuda; Hiroyuki Yasojima; Touko Inao; Tomofumi Osako; Masato Takahashi; Nobumoto Tomioka; Yumi Endo; Mitsuchika Hosoda; Hiroyoshi Doihara; Shinichiro Miyoshi; Hiroko Yamashita

  Breast cancer research : BCR, 02 Jul. 2016

  
• Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria.

  Hiroshi Katayama; Yukinori Kurokawa; Kenichi Nakamura; Hiroyuki Ito; Yukihide Kanemitsu; Norikazu Masuda; Yasuhiro Tsubosa; Toyomi Satoh; Akira Yokomizo; Haruhiko Fukuda; Mitsuru Sasako

  Surgery today, Jun. 2016

  
• A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.

  Masahiro Kashiwaba; Yoshinori Ito; Shintaro Takao; Hiroyoshi Doihara; Yoshiaki Rai; Kazumitsu Kanatani; Shigemitsu Takashima; Norikazu Masuda

  Japanese journal of clinical oncology, May 2016

  
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon

  The Lancet. Oncology, Apr. 2016

  
• Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.

  Takayuki Ueno; Shigehira Saji; Masahiro Sugimoto; Norikazu Masuda; Katsumasa Kuroi; Nobuaki Sato; Hiroyuki Takei; Yutaka Yamamoto; Shinji Ohno; Hiroko Yamashita; Kazufumi Hisamatsu; Kenjiro Aogi; Hiroji Iwata; Shigeru Imoto; Hironobu Sasano; Masakazu Toi

  BMC cancer, 16 Mar. 2016

  Access this paper :

  
• Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  Arlene Chan; Suzette Delaloge; Frankie A Holmes; Beverly Moy; Hiroji Iwata; Vernon J Harvey; Nicholas J Robert; Tajana Silovski; Erhan Gokmen; Gunter von Minckwitz; Bent Ejlertsen; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Marc Buyse; Ira Gore; John Smith 2nd; Graydon Harker; Norikazu Masuda; Katarina Petrakova; Angel Guerrero Zotano; Nicholas Iannotti; Gladys Rodriguez; Pierfrancesco Tassone; Alvin Wong; Richard Bryce; Yining Ye; Bin Yao; Miguel Martin

  The Lancet. Oncology, Mar. 2016

  
• Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

  Gabriel N Hortobagyi; David Chen; Martine Piccart; Hope S Rugo; Howard A Burris 3rd; Kathleen I Pritchard; Mario Campone; Shinzaburo Noguchi; Alejandra T Perez; Ines Deleu; Mikhail Shtivelband; Norikazu Masuda; Shaker Dakhil; Ian Anderson; Douglas M Robinson; Wei He; Abhishek Garg; E Robert McDonald 3rd; Hans Bitter; Alan Huang; Tetiana Taran; Thomas Bachelot; Fabienne Lebrun; David Lebwohl; José Baselga

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 Feb. 2016

  
• Prognosis after mastectomy versus repeat lumpectomy in patients with ipsilateral breast cancer recurrence: A propensity score analysis

  Yoshida, A.; Takahashi, O.; Okumura, Y.; Arima, N.; Nakatsukasa, K.; Tanabe, M.; Shien, T.; Masuda, N.; Tanaka, S.; Komoike, Y.; Taguchi, T.; Iwase, T.; Nishimura, R.; Inaji, H.; Yamauchi, H.; Ishitobi, M.

  European Journal of Surgical Oncology, 2016

  
• The challenge to overcome triple-negative breast cancer heterogeneity

  Masuda, H.; Masuda, N.

  Personalized Treatment of Breast Cancer, 2016

  
• Local recurrence risk after previous salvage mastectomy

  Tanabe, M.; Iwase, T.; Okumura, Y.; Yoshida, A.; Masuda, N.; Nakatsukasa, K.; Shien, T.; Tanaka, S.; Komoike, Y.; Taguchi, T.; Arima, N.; Nishimura, R.; Inaji, H.; Ishitobi, M.

  European Journal of Surgical Oncology, 2016

  
• Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer.

  Tomoharu Sugie; Takayuki Kinoshita; Norikazu Masuda; Terumasa Sawada; Akira Yamauchi; Katsumasa Kuroi; Tetsuya Taguchi; Hiroko Bando; Hiroyasu Yamashiro; Tecchuu Lee; Nobuhiko Shinkura; Hironori Kato; Takafumi Ikeda; Kenichi Yoshimura; Hanae Ueyama; Masakazu Toi

  Annals of surgical oncology, Jan. 2016

  
• Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.

  Hirofumi Mukai; Koji Arihiro; Chikako Shimizu; Norikazu Masuda; Yumi Miyagi; Takeshi Yamaguchi; Takashi Yoshida

  Breast cancer (Tokyo, Japan), Jan. 2016

  
• Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis.

  Jun Yamamura; Norikazu Masuda; Hiroyuki Yasojima; Makiko Mizutani; Keiko Kuriyama; Shoji Nakamori; Mitsugu Sekimoto; Masayuki Mano; Eiichi Tanaka; Masahiro Nonaka

  Breast care (Basel, Switzerland), Dec. 2015

  
• Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.

  Kenichi Inoue; Katsumasa Kuroi; Satoru Shimizu; Yoshiaki Rai; Kenjiro Aogi; Norikazu Masuda; Takahiro Nakayama; Hiroji Iwata; Yuichiro Nishimura; Alison Armour; Yasutsuna Sasaki

  International journal of clinical oncology, Dec. 2015

  
• Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.

  Katsumasa Kuroi; Masakazu Toi; Shinji Ohno; Seigo Nakamura; Hiroji Iwata; Norikazu Masuda; Nobuaki Sato; Hitoshi Tsuda; Masafumi Kurosumi; Futoshi Akiyama

  Breast cancer (Tokyo, Japan), Nov. 2015

  
• Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan.

  Mika Miyashita; Shinji Ohno; Akemi Kataoka; Eriko Tokunaga; Norikazu Masuda; Tadahiko Shien; Kimiko Kawabata; Miyako Takahashi

  Cancer nursing, Nov. 2015

  
• Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.

  Norikazu Masuda; Yutaka Tokuda; Seigo Nakamura; Ryutaro Shimazaki; Yoshinori Ito; Kazuo Tamura

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Oct. 2015

  
• Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.

  Takashi Hojo; Norikazu Masuda; Tomonori Mizutani; Taro Shibata; Takayuki Kinoshita; Kenji Tamura; Fumikata Hara; Tomomi Fujisawa; Kenichi Inoue; Shigehira Saji; Kenichi Nakamura; Haruhiko Fukuda; Hiroji Iwata

  Japanese journal of clinical oncology, Oct. 2015

  
• Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

  Hirofumi Mukai; Norikazu Masuda; Hiroshi Ishiguro; Ayako Mitsuma; Takashi Shibata; Jun Yamamura; Masakazu Toi; Aiko Watabe; Akiko Sarashina; Martina Uttenreuther-Fischer; Yuichi Ando

  Cancer chemotherapy and pharmacology, Oct. 2015

  
• Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.

  Katsumasa Kuroi; Masakazu Toi; Shinji Ohno; Seigo Nakamura; Hiroji Iwata; Norikazu Masuda; Nobuaki Sato; Hitoshi Tsuda; Masafumi Kurosumi; Futoshi Akiyama

  Breast cancer (Tokyo, Japan), Sep. 2015

  
• Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.

  Hiroyasu Yamshiro; Hiroji Iwata; Norikazu Masuda; Naohito Yamamoto; Reiki Nishimura; Shoichiro Ohtani; Nobuaki Sato; Masato Takahashi; Takako Kamio; Kosuke Yamazaki; Tsuyoshi Saito; Makoto Kato; Tecchuu Lee; Shinji Ohno; Katsumasa Kuroi; Toshimi Takano; Masahiro Takada; Shinji Yasuno; Satoshi Morita; Masakazu Toi

  International journal of clinical oncology, Aug. 2015

  
• Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.

  Hiroyasu Yamshiro; Hiroji Iwata; Norikazu Masuda; Naohito Yamamoto; Reiki Nishimura; Shoichiro Ohtani; Nobuaki Sato; Masato Takahashi; Takako Kamio; Kosuke Yamazaki; Tsuyoshi Saito; Makoto Kato; Tecchuu Lee; Shinji Ohno; Katsumasa Kuroi; Toshimi Takano; Masahiro Takada; Shinji Yasuno; Satoshi Morita; Masakazu Toi

  International journal of clinical oncology, Aug. 2015

  
• A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: treatment planning and quality assurance.

  Yuki Otani; Takayuki Nose; Takushi Dokiya; Toshiaki Saeki; Yu Kumazaki; Shuuji Asahi; Iwao Tsukiyama; Ichirou Fukuda; Hiroshi Sekine; Naoto Shikama; Takao Takahashi; Ken Yoshida; Tadayuki Kotsuma; Norikazu Masuda; Eisaku Yoden; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi

  Radiation oncology (London, England), 04 Jun. 2015

  
• Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting.

  Masakazu Toi; Norikazu Masuda; Hiroshi Ishiguro; Shigehira Saji; Shinji Ohno; Louis W C Chow

  The International journal of biological markers, Apr. 2015

  
• Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

  Yoshimasa Kosaka; Yoshiaki Rai; Norikazu Masuda; Toshimi Takano; Toshiaki Saeki; Seigo Nakamura; Ryutaro Shimazaki; Yoshinori Ito; Yutaka Tokuda; Kazuo Tamura

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Apr. 2015

  
• The present state and perception of young women with breast cancer towards breast reconstructive surgery.

  Keiko Nozawa; Miho Ichimura; Akira Oshima; Eriko Tokunaga; Norikazu Masuda; Atsuko Kitano; Atsushi Fukuuchi; Ono Shinji

  International journal of clinical oncology, Apr. 2015

  
• Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.

  Hiroji Iwata; Hirofumi Fujii; Norikazu Masuda; Hirofumi Mukai; Yuichiro Nishimura; Koichi Katsura; Catherine E Ellis; Robert C Gagnon; Seigo Nakamura

  Breast cancer (Tokyo, Japan), Mar. 2015

  
• Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence

  Okumura, Y.; Nishimura, R.; Nakatsukasa, K.; Yoshida, A.; Masuda, N.; Tanabe, M.; Shien, T.; Tanaka, S.; Arima, N.; Komoike, Y.; Taguchi, T.; Iwase, T.; Inaji, H.; Ishitobi, M.

  European Journal of Surgical Oncology, 2015

  
• [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

  Yoshinori Ito; Norikazu Masuda; Hiroji Iwata; Hirofumi Mukai; Jun Horiguchi; Yutaka Tokuda; Katsumasa Kuroi; Asuka Mori; Nobutsugu Ohno; Shinzaburo Noguchi

  Gan to kagaku ryoho. Cancer & chemotherapy, Jan. 2015

  
• Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.

  Naoki Hayashi; Naoki Niikura; Norikazu Masuda; Seiki Takashima; Rikiya Nakamura; Ken-ichi Watanabe; Chizuko Kanbayashi; Mayumi Ishida; Yasuo Hozumi; Michiko Tsuneizumi; Naoto Kondo; Yoichi Naito; Yayoi Honda; Akira Matsui; Tomomi Fujisawa; Risa Oshitanai; Hiroyuki Yasojima; Hideko Yamauchi; Shigehira Saji; Hiroji Iwata

  Breast cancer research and treatment, Jan. 2015

  
• The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.

  Seung Jin Kim; Norikazu Masuda; Fumine Tsukamoto; Hideo Inaji; Futoshi Akiyama; Hiroshi Sonoo; Junichi Kurebayashi; Katsuhide Yoshidome; Masahiko Tsujimoto; Hiroyuki Takei; Shinobu Masuda; Seigo Nakamura; Shinzaburo Noguchi

  Cancer letters, 28 Dec. 2014

  
• [Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].

  Akiko Enami; Norikazu Masuda; Jun Yamamura; Makiko Mizutani; Hiroyuki Yasojima; Ayako Shikata; Miyuki Masaoka; Seiko Takada; Nao Bamba; Mie Yamamoto; Megumi Abe; Katsuya Makihara

  Gan to kagaku ryoho. Cancer & chemotherapy, Nov. 2014

  
• Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study.

  Akemi Kataoka; Eriko Tokunaga; Norikazu Masuda; Tadahiko Shien; Kimiko Kawabata; Mika Miyashita

  Breast cancer (Tokyo, Japan), Nov. 2014

  
• Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

  Shinzaburo Noguchi; Norikazu Masuda; Hiroji Iwata; Hirofumi Mukai; Jun Horiguchi; Puttisak Puttawibul; Vichien Srimuninnimit; Yutaka Tokuda; Katsumasa Kuroi; Hirotaka Iwase; Hideo Inaji; Shozo Ohsumi; Woo-Chul Noh; Takahiro Nakayama; Shinji Ohno; Yoshiaki Rai; Byeong-Woo Park; Ashok Panneerselvam; Mona El-Hashimy; Tetiana Taran; Tarek Sahmoud; Yoshinori Ito

  Breast cancer (Tokyo, Japan), Nov. 2014

  
• Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR.

  Makoto Ishitobi; Yasuhiro Okumura; Reiki Nishimura; Katsuhiko Nakatsukasa; Masahiko Tanabe; Atsushi Yoshida; Norikazu Masuda; Tadahiko Shien; Satoru Tanaka; Yoshifumi Komoike; Nobuyuki Arima; Tetsuya Taguchi; Hideo Inaji

  Breast cancer (Tokyo, Japan), Nov. 2014

  
• Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.

  Mari S Oba; Shigeru Imoto; Uhi Toh; Noriaki Wada; Masaya Kawada; Masahiro Kitada; Norikazu Masuda; Tetsuya Taguchi; Shigeki Minami; Hiromitsu Jinno; Junichi Sakamoto; Satoshi Morita

  Japanese journal of clinical oncology, Sep. 2014

  
• Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

  Takayuki Ueno; Norikazu Masuda; Takeharu Yamanaka; Shigehira Saji; Katsumasa Kuroi; Nobuaki Sato; Hiroyuki Takei; Yutaka Yamamoto; Shinji Ohno; Hiroko Yamashita; Kazufumi Hisamatsu; Kenjiro Aogi; Hiroji Iwata; Hironobu Sasano; Masakazu Toi

  International journal of clinical oncology, Aug. 2014

  
• Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.

  Naoki Niikura; Naoki Hayashi; Norikazu Masuda; Seiki Takashima; Rikiya Nakamura; Ken-ichi Watanabe; Chizuko Kanbayashi; Mayumi Ishida; Yasuo Hozumi; Michiko Tsuneizumi; Naoto Kondo; Yoichi Naito; Yayoi Honda; Akira Matsui; Tomomi Fujisawa; Risa Oshitanai; Hiroyuki Yasojima; Yutaka Tokuda; Shigehira Saji; Hiroji Iwata

  Breast cancer research and treatment, Aug. 2014

  
• Phase II Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer

  Takashima Tsutomu; Nakayama Takahiro; Yoshidome Katsuhide; Kawajiri Hidemi; Kamigaki Shunji; Tsurutani Junji; Arai Takashi; Ito Toshikazu; Komoike Yoshihumi; Doi Takako; Masuda Norikazu; Miyauchi Keisuke; Miyoshi Yasuo; Sakamoto Junichi; Morita Satoshi; Taguchi Tetsuya

  ANTICANCER RESEARCH, Jul. 2014

  
• Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer

  Takashima T; Nakayama T; Yoshidome K; Kawajiri H; Kamigaki S; Tsurutani J; Arai T; Ito T; Komoike Y; Doi T; Masuda N; Miyauchi K; Miyoshi Y; Sakamoto J; Morita S; Taguchi T

  Anticancer Research, 01 Jul. 2014

  
• Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

  Tsutomu Takashima; Takahiro Nakayama; Katsuhide Yoshidome; Hidemi Kawajiri; Shunji Kamigaki; Junji Tsurutani; Takashi Arai; Toshikazu Ito; Yoshihumi Komoike; Takako Doi; Norikazu Masuda; Keisuke Miyauchi; Yasuo Miyoshi; Junichi Sakamoto; Satoshi Morita; Tetsuya Taguchi

  Anticancer research, Jul. 2014

  
• Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

  Masashi Ando; Hideko Yamauchi; Kenjiro Aogi; Satoru Shimizu; Hiroji Iwata; Norikazu Masuda; Naohito Yamamoto; Kenichi Inoue; Shinji Ohono; Katsumasa Kuroi; Tetsutaro Hamano; Tamie Sukigara; Yasuhiro Fujiwara

  Breast cancer research and treatment, Jun. 2014

  
• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

  Fabrice André; Ruth O'Regan; Mustafa Ozguroglu; Masakazu Toi; Binghe Xu; Guy Jerusalem; Norikazu Masuda; Sharon Wilks; Francis Arena; Claudine Isaacs; Yoon-Sim Yap; Zsuzsanna Papai; Istvan Lang; Anne Armstrong; Guillermo Lerzo; Michelle White; Kunwei Shen; Jennifer Litton; David Chen; Yufen Zhang; Shyanne Ali; Tetiana Taran; Luca Gianni

  The Lancet. Oncology, May 2014

  
• Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.

  Morihiko Kimura; Takeshi Tominaga; Izo Kimijima; Yuichi Takatsuka; Shigemitsu Takashima; Yasuo Nomura; Fujio Kasumi; Akihiro Yamaguchi; Norikazu Masuda; Shinzaburo Noguchi; Nobuoki Eshima

  Breast cancer (Tokyo, Japan), May 2014

  
• [Effect of oral dexamethasone given 24 hours previously on docetaxel-induced edema: a retrospective study].

  Ai Kato; Norikazu Masuda; Katsuya Makihara; Hiroyuki Ueno; Kazuhiro Hirohata; Kazutaka Yamauchi; Hiroyuki Yasojima; Makiko Mizutani; Jun Yamamura; Katsuya Komori

  Gan to kagaku ryoho. Cancer & chemotherapy, Feb. 2014

  
• Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

  J Thaddeus Beck; Gabriel N Hortobagyi; Mario Campone; Fabienne Lebrun; Ines Deleu; Hope S Rugo; Barbara Pistilli; Norikazu Masuda; Lowell Hart; Bohuslav Melichar; Shaker Dakhil; Matthias Geberth; Martina Nunzi; Daniel Y C Heng; Thomas Brechenmacher; Mona El-Hashimy; Shyanne Douma; Francois Ringeisen; Martine Piccart

  Breast cancer research and treatment, Feb. 2014

  
• Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: A multicenter retrospective observational study (JBCRG-C03 study)

  Takada, M.; Ishiguro, H.; Nagai, S.; Ohtani, S.; Kawabata, H.; Yanagita, Y.; Hozumi, Y.; Shimizu, C.; Takao, S.; Sato, N.; Kosaka, Y.; Sagara, Y.; Iwata, H.; Ohno, S.; Kuroi, K.; Masuda, N.; Yamashiro, H.; Sugimoto, M.; Kondo, M.; Naito, Y.; Sasano, H.; Inamoto, T.; Morita, S.; Toi, M.

  Breast Cancer Research and Treatment, 2014

  Access this paper :

  
• A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2- negative primary breast cancer

  Masuda, N.; Higaki, K.; Takano, T.; Matsunami, N.; Morimoto, T.; Ohtani, S.; Mizutani, M.; Miyamoto, T.; Kuroi, K.; Ohno, S.; Morita, S.; Toi, M.

  Cancer Chemotherapy and Pharmacology, 2014

  
• Primary chest wall abscess mimicking a breast tumor that occurred after blunt chest trauma: a case report.

  Yusuke Yamaoka; Jun Yamamura; Norikazu Masuda; Hiroyuki Yasojima; Makiko Mizutani; Shoji Nakamori; Toru Kanazawa; Keiko Kuriyama; Masayuki Mano; Mitsugu Sekimoto

  Case reports in medicine, 2014

  
• Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer

  Masuda N; Mukai H; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Ebisawa R; Uttenreuther-Fischer M; Ando Y

  CANCER RESEARCH, 15 Dec. 2013

  
• Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.

  Javier Cortés; Sandra M Swain; Iveta Kudaba; Maik Hauschild; Taral Patel; Elza Grincuka; Norikazu Masuda; Virginia McNally; Graham Ross; Mike Brewster; Jean-François Marier; My My Trinh; Amit Garg; Ihsan Nijem; Jennifer Visich; Bert L Lum; José Baselga

  Anti-cancer drugs, Nov. 2013

  
• Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

  Ohno, S.; Chow, L.W.C.; Sato, N.; Masuda, N.; Sasano, H.; Takahashi, F.; Bando, H.; Iwata, H.; Morimoto, T.; Kamigaki, S.; Nakayama, T.; Nakamura, S.; Kuroi, K.; Aogi, K.; Kashiwaba, M.; Yamashita, H.; Hisamatsu, K.; Ito, Y.; Yamamoto, Y.; Ueno, T.; Fakhrejahani, E.; Yoshida, N.; Toi, M.

  Breast Cancer Research and Treatment, Nov. 2013

  
• The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.

  Yoshiaki Sagara; Kazuhiko Sato; Eisuke Fukuma; Kenji Higaki; Mitsuhiro Mizutani; Akihiko Osaki; Toshimi Takano; Yutaka Tokuda; Shinji Ohno; Norikazu Masuda; Masato Suzuki; Toshiaki Saeki

  Japanese journal of clinical oncology, Sep. 2013

  
• A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).

  Kenjiro Aogi; Toshiaki Saeki; Seigo Nakamura; Masahiro Kashiwaba; Nobuaki Sato; Norikazu Masuda; Yoshiaki Rai; Shinji Ohno; Katsumasa Kuroi; Reiki Nishimura; Keiko Miyakoda; Futoshi Akiyama; Masafumi Kurosumi; Tadashi Ikeda

  International journal of clinical oncology, Aug. 2013

  
• Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study.

  Masakazu Toi; Saya Hirota; Ai Tomotaki; Nobuaki Sato; Yasuo Hozumi; Keisei Anan; Takeshi Nagashima; Yutaka Tokuda; Norikazu Masuda; Shozo Ohsumi; Shinji Ohno; Masato Takahashi; Hironori Hayashi; Seiichiro Yamamoto; Yasuo Ohashi

  Current nutrition and food science, Aug. 2013

  
• A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.

  Hiroji Iwata; Norikazu Masuda; Shinji Ohno; Yoshiaki Rai; Yasuyuki Sato; Shozo Ohsumi; Satoshi Hashigaki; Yoshinori Nishizawa; Masahiro Hiraoka; Tadaoki Morimoto; Hironobu Sasano; Toshiaki Saeki; Shinzaburo Noguchi

  Breast cancer research and treatment, Jun. 2013

  
• Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.

  Makoto Ishitobi; Yasuhiro Okumura; Nobuyuki Arima; Atsushi Yoshida; Katsuhiko Nakatsukasa; Takuji Iwase; Tadahiko Shien; Norikazu Masuda; Satoru Tanaka; Masahiko Tanabe; Takehiro Tanaka; Yoshifumi Komoike; Tetsuya Taguchi; Reiki Nishimura; Hideo Inaji

  Annals of surgical oncology, Jun. 2013

  
• Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.

  Kenjiro Aogi; Yoshiaki Rai; Yoshinori Ito; Norikazu Masuda; Junichiro Watanabe; Jun Horiguchi; Takuto Tokudome; Shigemitsu Takashima

  Cancer chemotherapy and pharmacology, Jun. 2013

  
• Novel effect of 2-aminoethoxydiphenylborate through inhibition of calcium sensitization induced by Rho kinase activation in human detrusor smooth muscle

  Shahab Nouval; Kajioka Shunichi; Takahashi Ryosuke; Hayashi Maya; Nakayama Shinsuke; Sakamoto Kazuyuki; Takeda Masahiro; Masuda Noriyuki; Naito Seiji

  EUROPEAN JOURNAL OF PHARMACOLOGY, 15 May 2013

  
• Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer : KMBOG0610B

  HAYASHI Hidetoshi; TSURUTANI Junji; SATOH Taro; MASUDA Norikazu; OKAMOTO Wataru; MORINAGA Ryotaro; TERASHIMA Masaaki; MIYAZAKI Masaki; OKAMOTO Isamu; NISHIDA Yukihiro; TOMINAGA Shusei; TOKUNAGA Yukihiko; YAMAGUCHI Masahide; SAKAMOTO Junichi; NAKAYAMA Takahiro; NAKAGAWA Kazuhiko

  01 Apr. 2013

  
• Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.

  Hidetoshi Hayashi; Junji Tsurutani; Taro Satoh; Norikazu Masuda; Wataru Okamoto; Ryotaro Morinaga; Masaaki Terashima; Masaki Miyazaki; Isamu Okamoto; Yukihiro Nishida; Shusei Tominaga; Yukihiko Tokunaga; Masahide Yamaguchi; Junichi Sakamoto; Takahiro Nakayama; Kazuhiko Nakagawa

  Breast cancer (Tokyo, Japan), Apr. 2013

  
• Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.

  Tetsuya Taguchi; Daigo Yamamoto; Norikazu Masuda; Koji Oba; Takahiro Nakayama; Takuya Nagata; Masaya Nomura; Katsuhide Yoshidome; Hiroshi Yoshino; Nobuki Matsunami; Masaru Miyashita; Yoshihiko Furuya; Takanori Ishida; Kazuyuki Wakita; Junichi Sakamoto; Shinzaburo Noguchi

  Cancer chemotherapy and pharmacology, Mar. 2013

  
• Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.

  Hiroji Iwata; Norikazu Masuda; Yasuaki Sagara; Takayuki Kinoshita; Seigo Nakamura; Yasuhiro Yanagita; Reiki Nishimura; Hirotaka Iwase; Shunji Kamigaki; Hiroyuki Takei; Hitoshi Tsuda; Nobuya Hayashi; Shinzaburo Noguchi

  Cancer, 15 Feb. 2013

  
• Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

  Charles S Cleeland; Jean-Jacques Body; Alison Stopeck; Roger von Moos; Lesley Fallowfield; Susan D Mathias; Donald L Patrick; Mark Clemons; Katia Tonkin; Norikazu Masuda; Allan Lipton; Richard de Boer; Stefania Salvagni; Celia Tosello Oliveira; Yi Qian; Qi Jiang; Roger Dansey; Ada Braun; Karen Chung

  Cancer, 15 Feb. 2013

  
• Experience in the use of Mohs paste for cutaneous lesions in advanced malignant tumor patients

  Morita, K.; Yoshitatsu, S.; Osaki, Y.; Ogawa, H.; Masuda, N.; Higashino, M.; Kawakami, M.

  Japanese Journal of Plastic Surgery, 2013

  
• Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306.

  Hirofumi Mukai; Toru Watanabe; Michihide Mitsumori; Hitoshi Tsuda; Seigo Nakamura; Norikazu Masuda; Naohito Yamamoto; Taro Shibata; Akihiro Sato; Hiroji Iwata; Kenjiro Aogi

  Oncology, 2013

  
• [Current situation and issues regarding preoperative chemotherapy for HER2-positive breast cancer].

  Makiko Mizutani; Norikazu Masuda; Hajime Abe; Jun Yamamura; Hiroyuki Yasojima; Yoshinori Kodama; Tomoko Umeda; Yoshimasa Kurumi; Masayuki Mano; Toru Tani

  Gan to kagaku ryoho. Cancer & chemotherapy, Dec. 2012

  
• A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.

  Tadahiko Shien; Kenichi Nakamura; Taro Shibata; Takayuki Kinoshita; Kenjiro Aogi; Tomomi Fujisawa; Norikazu Masuda; Kenichi Inoue; Haruhiko Fukuda; Hiroji Iwata

  Japanese journal of clinical oncology, Oct. 2012

  
• [Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)].

  Norikazu Masuda; Masakazu Toi; Katsumasa Kuroi

  Nihon rinsho. Japanese journal of clinical medicine, Sep. 2012

  
• A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.

  Kenjiro Aogi; Hiroshi Sakai; Hirohisa Yoshizawa; Norikazu Masuda; Nobuyuki Katakami; Yasuhiro Yanagita; Kenichi Inoue; Masaru Kuranami; Mitsuhiro Mizutani; Noriyuki Masuda

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Jul. 2012

  
• Prognosis of early breast cancer patients treated with sentinel node biopsy: A prospective study from the Japanese society for sentinel node navigation surgery

  Imoto Shigeru; Aikou Takashi; Takei Hiroyuki; Wada Noriaki; Aihara Tomohiko; Inaba Masaaki; Motomura Kazuyoshi; Masuda Norikazu; Nagashima Takeshi; Jinno Hiromitsu; Miura Daishu; Saito Mari; Morita Satoshi; Sakamoto Junichi; Kitajima Masaki

  JOURNAL OF CLINICAL ONCOLOGY, 20 May 2012

  
• [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].

  Norikazu Masuda; Hiroyuki Yasojima; Makiko Mizutani; Jun Yamamura

  Gan to kagaku ryoho. Cancer & chemotherapy, Apr. 2012

  
• Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

  Norikazu Masuda; Yasuaki Sagara; Takayuki Kinoshita; Hiroji Iwata; Seigo Nakamura; Yasuhiro Yanagita; Reiki Nishimura; Hirotaka Iwase; Shunji Kamigaki; Hiroyuki Takei; Shinzaburo Noguchi

  The Lancet. Oncology, Apr. 2012

  
• Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.

  Seigo Nakamura; Masashi Ando; Norikazu Masuda; Kenjiro Aogi; Hiroyo Ino; Hiroji Iwata; Yutaka Tokuda; Naohito Yamamoto; Hiroi Kasai; Masahiko Takeuchi; Hitoshi Tsuda; Futoshi Akiyama; Masafumi Kurosumi; Yasuhiro Fujiwara

  Clinical breast cancer, Feb. 2012

  
• Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.

  Masahiro Takada; Shigehira Saji; Norikazu Masuda; Katsumasa Kuroi; Nobuaki Sato; Hiroyuki Takei; Yutaka Yamamoto; Shinji Ohno; Hiroko Yamashita; Kazufumi Hisamatsu; Kenjiro Aogi; Hiroji Iwata; Takayuki Ueno; Hironobu Sasano; Masakazu Toi

  Breast (Edinburgh, Scotland), Feb. 2012

  
• Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique

  Takada, M.; Sugimoto, M.; Ohno, S.; Kuroi, K.; Sato, N.; Bando, H.; Masuda, N.; Iwata, H.; Kondo, M.; Sasano, H.; Chow, L.W.C.; Inamoto, T.; Naito, Y.; Tomita, M.; Toi, M.

  Breast Cancer Research and Treatment, 2012

  
• A phase II study of eribulin in Japanese patients with: Heavily pretreated metastatic breast cancer

  Aogi, K.; Iwata, H.; Masuda, N.; Mukai, H.; Yoshida, M.; Rai, Y.; Taguchi, K.; Sasaki, Y.; Takashima, S.

  Annals of Oncology, 2012

  
• Male breast cancer originating in an accessory mammary gland in the axilla: a case report.

  Jun Yamamura; Norikazu Masuda; Yoshinori Kodama; Hiroyuki Yasojima; Makiko Mizutani; Keiko Kuriyama; Masayuki Mano; Shoji Nakamori; Mitsugu Sekimoto

  Case reports in medicine, 2012

  
• Objective and longitudinal assessment of dermatitis after postoperative accelerated partial breast irradiation using high-dose-rate interstitial brachytherapy in patients with breast cancer treated with breast conserving therapy: reduction of moisture deterioration by APBI.

  Eiichi Tanaka; Hideya Yamazaki; Ken Yoshida; Tadashi Takenaka; Norikazu Masuda; Tadayuki Kotsuma; Yasuo Yoshioka; Takehiro Inoue

  International journal of radiation oncology, biology, physics, 15 Nov. 2011

  
• First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.

  Kenjiro Aogi; Norikazu Masuda; Shinji Ohno; Takashi Oda; Hiroji Iwata; Masahiro Kashiwaba; Yasuhiro Fujiwara; Shunji Kamigaki; Yoshinori Ito; Takayuki Ueno; Shigemitsu Takashima

  Breast cancer research and treatment, Oct. 2011

  
• Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

  Hiroji Iwata; Nobuaki Sato; Norikazu Masuda; Seigo Nakamura; Naohito Yamamoto; Katsumasa Kuroi; Masafumi Kurosumi; Hitoshi Tsuda; Futoshi Akiyama; Yasuo Ohashi; Masakazu Toi

  Japanese journal of clinical oncology, Jul. 2011

  
• Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition

  TOI Masakazu; SAJI Shigehira; MASUDA Norikazu; KUROI Katsumasa; SATO Nobuaki; TAKEI Hiroyuki; YAMAMOTO Yutaka; OHNO Shinji; YAMASHITA Hiroko; HISAMATSU Kazufumi; AOGI Kenjiro; IWATA Hiroji; TAKADA Masahiro; UENO Takayuki; SAJI Shigetoyo; CHANPLAKORN Niramol; SUZUKI Takashi; SASANO Hironobu

  Cancer Sci, 10 Apr. 2011

  
• Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.

  Daisuke Ota; Koshi Mimori; Takehiko Yokobori; Masaaki Iwatsuki; Akemi Kataoka; Norikazu Masuda; Hideshi Ishii; Shinji Ohno; Masaki Mori

  International journal of oncology, Apr. 2011

  
• Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.

  Masakazu Toi; Shigehira Saji; Norikazu Masuda; Katsumasa Kuroi; Nobuaki Sato; Hiroyuki Takei; Yutaka Yamamoto; Shinji Ohno; Hiroko Yamashita; Kazufumi Hisamatsu; Kenjiro Aogi; Hiroji Iwata; Masahiro Takada; Takayuki Ueno; Shigetoyo Saji; Niramol Chanplakorn; Takashi Suzuki; Hironobu Sasano

  Cancer science, Apr. 2011

  
• Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

  Norikazu Masuda; Hiraji Iwata; Yoshiaki Rai; Keisei Anan; Toru Takeuchi; Norio Kohno; Hiroyuki Takei; Yasuhiro Yanagita; Shinzaburo Noguchi

  Breast cancer research and treatment, Apr. 2011

  
• Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients.

  Hiroko Masuda; Norikazu Masuda; Yoshinori Kodama; Masami Ogawa; Michiko Karita; Jun Yamamura; Kazunori Tsukuda; Hiroyoshi Doihara; Shinichiro Miyoshi; Masayuki Mano; Shoji Nakamori; Toshimasa Tsujinaka

  Cancer chemotherapy and pharmacology, Apr. 2011

  
• The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in japanese postmenopausal early breast cancer patients: Final results of national surgical adjuvant study BC 04, the TEAM Japan sub-study

  Hozumi, Y.; Suemasu, K.; Takei, H.; Aihara, T.; Takehara, M.; Saito, T.; Ohsumi, S.; Masuda, N.; Ohashi, Y.

  Annals of Oncology, 2011

  
• Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: Results of N-SAS BC 04, the TEAM Japan substudy

  Aihara, T.; Suemasu, K.; Takei, H.; Hozumi, Y.; Takehara, M.; Saito, T.; Ohsumi, S.; Masuda, N.; Ohashi, Y.

  Oncology, 2011

  
• Correlation between docetaxel-induced skin toxicity and the use of steroids and H ₂ blockers: A multi-institution survey

  Kawaguchi, K.; Ishiguro, H.; Morita, S.; Nakamura, S.; Ohno, S.; Masuda, N.; Iwata, H.; Aogi, K.; Kuroi, K.; Toi, M.

  Breast Cancer Research and Treatment, 2011

  Access this paper :

  
• Objective assessment of dermatitis following post-operative radiotherapy in patients with breast cancer treated with breast-conserving treatment.

  Ken Yoshida; Hideya Yamazaki; Tadashi Takenaka; Eiichi Tanaka; Tadayuki Kotsuma; Yuka Fujita; Norikazu Masuda; Keiko Kuriyama; Mineo Yoshida; Tsunehiko Nishimura

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], Nov. 2010

  
• Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor

  YAMAMOTO Yutaka; MASUDA Norikazu; OHTAKE Tohru; YAMASHITA Hiroko; SAJI Shigehira; KIMIJIMA Izo; KASAHARA Yoshio; ISHIKAWA Takashi; SAWAKI Masataka; HOZUMI Yasuo; IWASE Hirotaka

  Breast Cancer, 01 Oct. 2010

  
• Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.

  Yutaka Yamamoto; Norikazu Masuda; Tohru Ohtake; Hiroko Yamashita; Shigehira Saji; Izo Kimijima; Yoshio Kasahara; Takashi Ishikawa; Masataka Sawaki; Yasuo Hozumi; Hirotaka Iwase

  Breast cancer (Tokyo, Japan), Oct. 2010

  
• PHASE II STUDY OF IRINOTECAN (CPT-11) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER (MBC): KMBOG0601

  Hayashi H; Tsurutani J; Satoh T; Sakamoto J; Masuda N; Tokunaga Y; Yamaguchi M; Tominaga S; Fukuoka M; Nakagawa K

  ANNALS OF ONCOLOGY, Oct. 2010

  
• Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).

  Hirofumi Mukai; Tsutomu Takashima; Yasuo Hozumi; Takanori Watanabe; Shigeru Murakami; Norikazu Masuda; Shoshu Mitsuyama; Tousei Ohmura; Tamiko Yajima; Yasuo Ohashi

  Japanese journal of clinical oncology, Aug. 2010

  
• Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.

  Masakazu Toi; Hiroji Iwata; Takeharu Yamanaka; Norikazu Masuda; Shinji Ohno; Seigo Nakamura; Takahiro Nakayama; Masahiro Kashiwaba; Shunji Kamigaki; Katsumasa Kuroi

  Cancer, 01 Jul. 2010

  
• Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.

  Takeshi Tominaga; Izo Kimijima; Morihiko Kimura; Yuichi Takatsuka; Shigemitsu Takashima; Yasuo Nomura; Fujio Kasumi; Akihiro Yamaguchi; Norikazu Masuda; Shinzaburo Noguchi; Nobuoki Eshima

  Japanese journal of clinical oncology, Jul. 2010

  
• Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.

  Tomohiko Aihara; Yuichi Takatsuka; Shozo Ohsumi; Kenjiro Aogi; Yasuo Hozumi; Shigeru Imoto; Hirofumi Mukai; Hiroji Iwata; Toru Watanabe; Chikako Shimizu; Kazuhiko Nakagami; Motoshi Tamura; Toshikazu Ito; Norikazu Masuda; Nobuo Ogino; Kazufumi Hisamatsu; Shoshu Mitsuyama; Hajime Abe; Shiro Tanaka; Takuhiro Yamaguchi; Yasuo Ohashi

  Breast cancer research and treatment, Jun. 2010

  
• Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.

  Norikazu Masuda; Takahiro Nakayama; Jun Yamamura; Shunji Kamigaki; Tetsuya Taguchi; Mai Hatta; Junichi Sakamoto

  Cancer chemotherapy and pharmacology, May 2010

  
• Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.

  Maki Tanaka; Yasushi Takamatsu; Keisei Anan; Shinji Ohno; Reiki Nishimura; Yutaka Yamamoto; Norikazu Masuda; Shoshu Mitsuyama; Kazuo Tamura

  Anti-cancer drugs, Apr. 2010

  
• Predictive factors for anthracycline-based chemotherapy for human breast cancer.

  Yasuo Miyoshi; Masafumi Kurosumi; Junichi Kurebayashi; Nariaki Matsuura; Masato Takahashi; Eriko Tokunaga; Chiyomi Egawa; Norikazu Masuda; Seishi Kono; Koji Morimoto; Seung Jin Kim; Masatsugu Okishiro; Tetsu Yanagisawa; Satsuki Ueda; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi

  Breast cancer (Tokyo, Japan), Apr. 2010

  
• Impact of 4-weekly capecitabine plus paclitaxel (XP) combination therapy for metastatic breast cancer: a multicenter phase II trial (KBCSG-0609)

  Yamamoto D; Taguchi T; Masuda N; Nakayama T; Nagata T; Nomura M; Yoshidome K; Yoshino H; Sakamoto J; Noguchi S

  EJC SUPPLEMENTS, Mar. 2010

  
• Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer.

  Masakazu Toi; Jeff Sperinde; Weidong Huang; Shigehira Saji; John Winslow; Xueguang Jin; Yuping Tan; Shinji Ohno; Seigo Nakamura; Hiroji Iwata; Norikazu Masuda; Kenjiro Aogi; Satoshi Morita; Christos Petropoulos; Michael Bates

  BMC cancer, 23 Feb. 2010

  
• Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: Results from a double-blind, phase II comparative study (FINDER1)

  Ohno, S.; Rai, Y.; Iwata, H.; Yamamoto, N.; Yoshida, M.; Iwase, H.; Masuda, N.; Nakamura, S.; Taniguchi, H.; Kamigaki, S.; Noguchi, S.

  Annals of Oncology, 2010

  
• Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].

  Tetsuya Taguchi; Norikazu Masuda; Takahiro Nakayama; Kazuyoshi Motomura; Fumine Tsukamoto; Kenzo Shimazu; Takashi Nomura; Takashi Morimoto; Hiroshi Yamamoto; Kazuyuki Wakita; Yoshiaki Nakano; Kohri Yoneda; Hideo Inaji; Yuichi Takatsuka; Shinzaburo Noguchi

  Oncology, 2010

  
• Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.

  Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fujiwara; Norikazu Masuda; Fumine Tsukamoto; Mitsue Saito; Shigeto Miura; Kenji Eguchi; Tetsu Shinkai; Masashi Ando; Toru Watanabe; Noriyuki Masuda; Yasuo Ohashi; Muneaki Sano; Shinzaburo Noguchi

  Breast cancer research and treatment, Jan. 2010

  
• Study of low-dose capecitabine monotherapy for metastatic breast cancer.

  Tetsuya Taguchi; Takahiro Nakayama; Norikazu Masuda; Katsuhide Yoshidome; Kenzou Akagi; Yukihiro Nishida; Yukinobu Yoshikawa; Nobuo Ogino; Chigusa Abe; Junichi Sakamoto; Shinzaburo Noguchi

  Chemotherapy, 2010

  
• Longitudinal practical measurement of skin color and moisture during and after breast-conserving therapy: influence of neoadjuvant systemic therapy.

  Hideya Yamazaki; Ken Yoshida; Tadayuki Kotsuma; Keiko Kuriyama; Norikazu Masuda; Takuya Nishimura; Kana Kobayashi; Takuji Tsubokura; Tsunehiko Nishimura

  Japanese journal of radiology, Oct. 2009

  
• Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.

  Chikako Shimizu; Norikazu Masuda; Kenichi Yoshimura; Hitoshi Tsuda; Masayuki Mano; Masashi Ando; Kenji Tamura; Yasuhiro Fujiwara

  Japanese journal of clinical oncology, Aug. 2009

  
• Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

  Katsumasa Kuroi; Kojiro Shimozuma; Yasuo Ohashi; Kazufumi Hisamatsu; Norikazu Masuda; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Shozo Ohsumi; Frederick H Hausheer

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Aug. 2009

  
• Computed radiography-based mammography with 50-microm pixel size: intra-individual comparison with film-screen mammography for diagnosis of breast cancers.

  Hiromitsu Onishi; Norikazu Masuda; Kayo Takechi; Takahiro Nakayama; Masayuki Tatsuta; Naoki Mihara; Manabu Takamura; Yutaka Inoue; Keiko Kuriyama; Yoshikazu Kotsuma; Hiroshi Furukawa; Takamichi Murakami; Hironobu Nakamura

  Academic radiology, Jul. 2009

  
• Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.

  Takanori Ishida; Takayoshi Kiba; Motohiro Takeda; Kotone Matsuyama; Satoshi Teramukai; Ryota Ishiwata; Norikazu Masuda; Yuichi Takatsuka; Shinzaburo Noguchi; Chikashi Ishioka; Masanori Fukushima; Noriaki Ohuchi

  Cancer chemotherapy and pharmacology, Jul. 2009

  
• Preoperative u-PAR gene expression in bone marrow indicates the potential power of recurrence in breast cancer cases.

  Koshi Mimori; Akemi Kataoka; Hiroshi Yamaguchi; Norikazu Masuda; Yoshimasa Kosaka; Hideshi Ishii; Shinji Ohno; Masaki Mori

  Annals of surgical oncology, Jul. 2009

  
• Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay.

  Yasuhiro Tamaki; Futoshi Akiyama; Takuji Iwase; Tomoyo Kaneko; Hitoshi Tsuda; Kazuhiko Sato; Shigeto Ueda; Masayuki Mano; Norikazu Masuda; Masashi Takeda; Masahiko Tsujimoto; Katsuhide Yoshidome; Hideo Inaji; Hiromu Nakajima; Yoshifumi Komoike; Tatsuki R Kataoka; Seigo Nakamura; Koyu Suzuki; Koichiro Tsugawa; Kenichi Wakasa; Tsuyoshi Okino; Yo Kato; Shinzaburo Noguchi; Nariaki Matsuura

  Clinical cancer research : an official journal of the American Association for Cancer Research, 15 Apr. 2009

  
• [Examination about the influence for daily life that nail and skin disorders induced by docetaxel in patients with breast cancer].

  Keisuke Kohama; Norikazu Masuda; Jun Yamamura; Makoto Ishitobi; Hiroko Masuda; Masami Ogawa; Kinuyo Todaka; Tomi Tanaka; Hiroyuki Ueno; Shoji Nakamori; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Apr. 2009

  
• Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan clinical oncology group trial (JCOG9802)

  Katsumata, N.; Watanabe, T.; Minami, H.; Aogi, K.; Tabei, T.; Sano, M.; Masuda, N.; Andoh, J.; Ikeda, T.; Shibata, T.; Takashima, S.

  Annals of Oncology, 2009

  
• Preliminary result of accelerated partial breast irradiation after breast-conserving surgery.

  Ken Yoshida; Takayuki Nose; Norikazu Masuda; Hideya Yamazaki; Tadayuki Kotsuma; Mineo Yoshida; Jun Yamamura; Hiroko Masuda; Eisei Shin; Hiroyuki Nakaba; Yoshifumi Komoike; Yukiko Tokuda; Masashi Takeda; Keiko Kuriyama

  Breast cancer (Tokyo, Japan), 2009

  
• A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy

  Maemondo M; Masuda N; Sekine I; Kubota K; Segawa Y; Shibuya M; Imamura F; Katakami N; Hida T; Takeo S; Isobe H; Kikuchi Y; Ando M; Yokoyama A; Miyao H; Fujii H; Sakai H; Yoshimori K; Genma A; Takeda Y; Masahiro T; Arai H; Ogura T; Koizumi W; Eguchi K; Kitagawa C; Sawa T; Atagi S; Ogawara M; Nishimura T; Negoro S; Kiura K; Shigeoka Y; Ichinose Y; Senba H

  Annals of Oncology, 2009

  
• Evaluation of suspicious nipple discharge by magnetic resonance mammography based on breast imaging reporting and data system magnetic resonance imaging descriptors.

  Yukiko Tokuda; Keiko Kuriyama; Atsushi Nakamoto; Soomi Choi; Kenji Yutani; Yuki Kunitomi; Takashi Haneda; Misa Kawai; Norikazu Masuda; Masashi Takeda; Hironobu Nakamura

  Journal of computer assisted tomography, Jan. 2009

  
• Phase I study of combination therapy with weekly paclitaxel and cyclophosphatamide for advanced or recurrent breast cancer

  Nakayama T; Masuda N; Yamamura J; Kamigaki S; Taguchi T; Hatta M; Sakamoto J

  BREAST CANCER RESEARCH, 2009

  
• [Mohs paste for unresectable local lesion of breast cancer].

  Hisataka Ogawa; Norikazu Masuda; Hiroko Masuda; Jun Yamamura; Shoji Nakamori; Toshimasa Tsujinaka; Sumiko Yoshitatu; Nanaho Nakashotani; Hiroyuki Ueno; Kazuyo Matsuyama; Yuji Hattori; Kinuyo Todaka; Atsuko Nishimura

  Gan to kagaku ryoho. Cancer & chemotherapy, Sep. 2008

  
• Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.

  Masakazu Toi; Seigo Nakamura; Katsumasa Kuroi; Hiroji Iwata; Shinji Ohno; Norikazu Masuda; Mikihiro Kusama; Kosuke Yamazaki; Kazuhumi Hisamatsu; Yasuyuki Sato; Masahiro Kashiwaba; Hiroshi Kaise; Masafumi Kurosumi; Hitoshi Tsuda; Futoshi Akiyama; Yasuo Ohashi; Yuichi Takatsuka

  Breast cancer research and treatment, Aug. 2008

  
• Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.

  Yasuo Miyoshi; Masafumi Kurosumi; Junichi Kurebayashi; Nariaki Matsuura; Masato Takahashi; Eriko Tokunaga; Chiyomi Egawa; Norikazu Masuda; Seung Jin Kim; Masatsugu Okishiro; Tetsu Yanagisawa; Satsuki Ueda; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi

  Cancer letters, 08 Jun. 2008

  
• Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.

  Yasuo Miyoshi; Masafumi Kurosumi; Junichi Kurebayashi; Nariaki Matsuura; Masato Takahashi; Eriko Tokunaga; Chiyomi Egawa; Norikazu Masuda; Seung Jin Kim; Masatsugu Okishiro; Tetsu Yanagisawa; Satsuki Ueda; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi

  Journal of cancer research and clinical oncology, May 2008

  
• Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.

  Norikazu Masuda; Tetsuya Taguchi; Takahiro Nakayama; Eiichi Shiba; Masahiro Watatani; Junichi Kurebayashi; Yuichi Takatsuka; Junichi Sakamoto; Shinzaburo Noguchi

  Cancer chemotherapy and pharmacology, May 2008

  
• Clinical usefulness of high-dose toremifene for patients failed by treatment with aromatase inhibitor

  Iwase H; Yamamoto Y; Ohtake T; Masuda N; Yamashita H; Saji S; Kimijime I; Kasahara Y; Ishikawa T; Sawaki M

  EJC SUPPLEMENTS, Apr. 2008

  
• Role of percutaneous transhepatic biliary drainage in patients with obstructive jaundice caused by local recurrence of gastric cancer.

  Tomoki Makino; Kazumasa Fujitani; Toshimasa Tsujinaka; Motohiro Hirao; Masaki Kashiwazaki; Shoji Nakamori; Masakazu Ikenaga; Hideyuki Mishima; Norikazu Masuda; Toshiro Sawamura

  Hepato-gastroenterology, 2008

  
• [A case report of inoperable gastric cancer demonstrating a clinical CR after chemo-radiation therapy employing weekly DOC].

  Yoshiaki Ohmura; Kazumasa Fujitani; Hideya Yamasaki; Motohiro Hirao; Masayoshi Yasui; Norikazu Masuda; Masaki Kashiwazaki; Masakazu Ikenaga; Michihiko Miyazaki; Koji Takami; Hideyuki Mishima; Shoji Nakamori; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Nov. 2007

  
• [Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)].

  Norikazu Masuda; Masakazu Toi; Yuichi Takatsuka; Seigo Nakamura; Hiroji Iwata; Shinji Ohno; Katsumasa Kuroi; Mikihiro Kusama; Kazufumi Hisamatsu; Kosuke Yamazaki; Shin Eisei; Yasuyuki Sato; Hiroshi Kaise; Masahiro Kashiwaba; Hirotaka Iwase; Masafumi Kurosumi; Hitoshi Tsuda; Futoshi Akiyama

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2007

  
• [Optimal chemotherapy for advanced and recurrent breast cancer patients].

  Norikazu Masuda

  Nihon rinsho. Japanese journal of clinical medicine, 28 Jun. 2007

  
• [Outpatient chemotherapy for breast cancer patients].

  Tomonori Tanei; Norikazu Masuda; Makoto Ishitobi; Kinuyo Todaka; Tomi Tanaka; Hiroyuki Ueno

  Nihon rinsho. Japanese journal of clinical medicine, 28 Jun. 2007

  
• Pectoralis myocutaneous flap with T-tube drainage for cervical anastomotic leakage after salvage operation

  Hirao, M.; Yoshitatsu, S.; Tsujinaka, T.; Nishiyama, A.; Fujitani, K.; Nakamori, S.; Sawamura, T.; Mishima, H.; Ikenaga, M.; Masuda, N.; Kashiwazaki, M.

  Esophagus, 2006

  
• An icteric type hepatocellular carcinoma with no detectable tumor in the liver: report of a case.

  Tomoki Makino; Shoji Nakamori; Masaki Kashiwazaki; Norikazu Masuda; Masakazu Ikenaga; Motohiro Hirao; Kazumasa Fujitani; Hideyuki Mishima; Toshiro Sawamura; Masashi Takeda; Masayuki Mano; Toshimasa Tsujinaka

  Surgery today, 2006

  
• Primary signet-ring cell carcinoma of the colon and rectum: report of eight cases and review of 154 Japanese cases.

  Tomoki Makino; Toshimasa Tsujinaka; Hideuki Mishima; Masakazu Ikenaga; Toshiro Sawamura; Shoji Nakamori; Kazumasa Fujitani; Motohiro Hirao; Masaki Kashiwazaki; Norikazu Masuda; Masashi Takeda; Masayuki Mano

  Hepato-gastroenterology, 2006

  
• [A case of successful resection for recurrent intraductal papillary mucinous adenocarcinoma].

  Masaki Kashiwazaki; Yutaka Takeda; Yasunori Hasuike; Norikazu Masuda; Masakazu Ikenaga; Motohiro Hirao; Kazumasa Fujitani; Hideyuki Mishima; Toshiro Sawamura; Shoji Nakamori; Masashi Takeda; Yoshiyuki Mano; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2005

  
• [A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].

  Shinya Yamashita; Motohiro Hirao; Toshimasa Tsujinaka; Toshiro Sawamura; Syoji Nakamori; Hideyuki Mishima; Kazumasa Fujitani; Masakazu Ikenaga; Masaki Kashiwazaki; Norikazu Masuda

  Gan to kagaku ryoho. Cancer & chemotherapy, Aug. 2005

  
• Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.

  Taka-Aki Masuda; Akemi Kataoka; Shinji Ohno; Shigeru Murakami; Koshi Mimori; Tohru Utsunomiya; Hiroshi Inoue; Shinichi Tsutsui; Junko Kinoshita; Norikazu Masuda; Noriyuki Moriyama; Masaki Mori

  International journal of oncology, Mar. 2005

  
• Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer

  Ohno, S.; Toi, M.; Kuroi, K.; Nakamura, S.; Iwata, H.; Kusama, M.; Masuda, N.; Yamazaki, K.; Hisamatsu, K.; Sato, Y.; Takatsuka, Y.; Shin, E.; Kaise, H.; Kurozumi, M.; Tsuda, H.; Akiyama, F.

  Biomedicine and Pharmacotherapy, 2005

  
• Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.

  Hiroji Iwata; Seigo Nakamura; Masakazu Toi; Eisei Shin; Norikazu Masuda; Shinji Ohno; Yuichi Takatsuka; Kazufumi Hisamatsu; Kosuke Yamazaki; Mikihiro Kusama; Hiroshi Kaise; Yasuyuki Sato; Katsumasa Kuroi; Futoshi Akiyama; Hitoshi Tsuda; Masafumi Kurosumi

  Breast cancer (Tokyo, Japan), 2005

  
• [Evaluation of prophylactic hepatic arterial infusion chemotherapy after curative hepatectomy for metastatic colorectal cancer].

  Masayoshi Tokuoka; Masaki Kashiwazaki; Yutaka Takeda; Yasunori Hasuike; Hideyuki Mishima; Masakazu Ikenaga; Norikazu Masuda; Motohiro Hirao; Kazumasa Fujitani; Toshiro Sawamura; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2004

  
• [Effectiveness of chemoradiotherapy for three cases of squamous cell anal carcinoma].

  Atsushi Takeno; Hideyuki Mishima; Masakazu Ikenaga; Norikazu Masuda; Masaki Kashiwazaki; Yutaka Takeda; Motohiro Hirao; Kazumasa Fujitani; Toshiro Sawamura; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2004

  
• [A case of disease-free survival of liver and lung metastases of rectal cancer resected for a total of five times].

  Masaki Kashiwazaki; Yutaka Takeda; Yasunori Hasuike; Hideyuki Mishima; Masakazu Ikenaga; Norikazu Masuda; Motohiro Hirao; Kazumasa Fujitani; Toshiro Sawamura; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2004

  
• [A case of long-term survival with recurrence leiomyosarcoma of the rectum treated by repeated local resections].

  Masakazu Ikenaga; Hideyuki Mishima; Masaki Kashiwazaki; Norikazu Masuda; Motohiro Hirao; Yutaka Takeda; Kazumasa Fujitani; Toshiro Sawamura; Toshimasa Tsujinaka

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2004

  
• High expression of two genes selected by iAFLP: a new prognostic factor of estrogen receptor-positive breast cancer.

  Noriko Aritake; Yasuhiro Tamaki; Norikazu Masuda; Yoshiaki Nakano; Takushi Monden; Shinzaburo Noguchi; Morito Monden

  Oncology reports, Aug. 2004

  
• [Surgical indication and significance of local therapy for first pulmonary metastases from colorectal cancer].

  Masayuki Tatsuta; Hideyuki Ishida; Hiroshi Furukawa; Makoto Fujishima; Kazuyoshi Yamamoto; Hitoshi Kato; Koji Esumi; Kentaro Kishi; Hiroyoshi Takemoto; Junzo Shimizu; Takahiro Nakayama; Hiroshi Imamura; Seizo Masutani; Takatoshi Kawasaki; Norikazu Masuda

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2003

  
• [A case of lymph node recurrence after curative operation of type 4 gastric cancer, successfully treated with TS-1].

  Kazuyoshi Yamamoto; Hiroshi Imamura; Hiroshi Furukawa; Hitoshi Kato; Koji Esumi; Norikazu Masuda; Junzo Shimizu; Hideyuki Ishida; Seizo Masutani; Masayuki Tatsuta; Takatoshi Kawasaki

  Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2003

  
• Anomalous systemic arterial supply to the basal segment of the left lung; report of a case

  Ishida, H.; Tatsuta, M.; Masutani, S.; Imamura, H.; Shimizu, J.; Masuda, N.; Kawasaki, T.; Furukawa, H.; Okazaki, H.; Miwa, H.; Inoue, Y.; Joko, T.

  Kyobu geka. The Japanese journal of thoracic surgery, 2003

  
• [Limits of surgical therapy for pulmonary metastasis from breast cancer].

  Masayuki Tatsuta; Norikazu Masuda; Hiroshi Furukawa; Kazuyoshi Yamamoto; Hitoshi Kato; Koji Esumi; Kotaro Kitani; Junzo Shimizu; Hiroshi Imamura; Hideyuki Ishida; Seizo Masutani; Takatoshi Kawasaki

  Gan to kagaku ryoho. Cancer & chemotherapy, Nov. 2002

  
• [A case report of hepatocellular carcinoma with portal thrombus responding to hepatic arterial infusion chemo-lipiodolization].

  Seizo Masutani; Junzo Shimizu; Masayuki Tatsuta; Hitoshi Katoh; Kotaro Kitani; Kouji Esumi; Norikazu Masuda; Hiroshi Imamura; Hideyuki Ishida; Hiroshi Furukawa; Hiromitsu Onishi; Kyo Tsuda; Yutaka Inoue; Kouichi Tomotsu; Tatsuhiko Usui

  Gan to kagaku ryoho. Cancer & chemotherapy, Nov. 2002

  
• [A case of metastatic gastric cancer treated with CDDP plus TS-1 and surgical resection].

  Junzo Shimizu; Seizo Masutani; Hiroshi Imamura; Hiroshi Furukawa; Hitoshi Kato; Kouji Ezumi; Norikazu Masuda; Hideyuki Ishida; Masayuki Tatsuta; Takatoshi Kawasaki

  Gan to kagaku ryoho. Cancer & chemotherapy, Nov. 2002

  
• Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry.

  Shingo Noura; Hirofumi Yamamoto; Tadashi Ohnishi; Norikazu Masuda; Takashi Matsumoto; Osamu Takayama; Hiroki Fukunaga; Yasuhiro Miyake; Masakazu Ikenaga; Masataka Ikeda; Mitsugu Sekimoto; Nariaki Matsuura; Morito Monden

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 Oct. 2002

  
• The novel germline mutation of hMSH2 gene in a case of a colon cancer patient without family history.

  Hideyuki Ishida; Hiroshi Furukawa; Masayuki Tatsuta; Seizo Masutani; Hiroshi Imamura; Junzo Shimizu; Norikazu Masuda; Takatoshi Kawasaki; Takashi Satomi; Kokichi Sugano; Noriko Fukayama; Naohiro Tomita

  Japanese journal of clinical oncology, Jul. 2002

  
• The relationship between the number of metastatic lymph nodes and prognosis of patients with Dukes C colon cancer

  Ishida, H.; Furukawa, H.; Tatsuta, M.; Masutani, S.; Imamura, H.; Shimizu, J.; Masuda, N.; Ezumi, K.; Kawasaki, T.; Satomi, T.

  Japanese Journal of Gastroenterological Surgery, 2002

  
• Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty

  Nagaoka N; Matsubara T; Okazaki K; Masuda N; Shikaura K; Hotta N

  Japanese Heart Journal, 07 Apr. 2001

  
• Management of axillary and internal mammary lymph nodes in primary breast cancer

  Masuda, N.; Tamaki, Y.; Noguchi, S.

  Nippon Geka Gakkai zasshi, 2001

  
• The significance of neoadjuvant intra-arterial chemotherapy for locally advanced breast cancer by different methods

  Tatsuta, M.; Furukawa, H.; Masutani, S.; Kato, H.; Esumi, K.; Masuda, N.; Shimizu, J.; Imamura, H.; Ikeda, M.; Ishida, H.; Kawasaki, T.; Satomi, T.; Hoshida, Y.

  Gan to kagaku ryoho. Cancer & chemotherapy, 2001

  
• A case of locally advanced breast cancer successfully treated with wide resection and reconstruction of chest wall with A-O metallic plates

  Imamura, H.; Tatsuta, M.; Masuda, N.; Miya, A.; Ezumi, K.; Shimizu, J.; Ikeda, M.; Ishida, H.; Masutani, S.; Kawasaki, T.; Furukawa, H.; Satomi, T.

  Gan to kagaku ryoho. Cancer & chemotherapy, 2001

  
• Single cell analysis of CAG repeat in brains of dentatorubral-pallidoluysian atrophy (DRPLA)

  Hashida H; Goto J; Suzuki T; Jeong S.Y; Masuda N; Ooie T; Tachiiri Y; Tsuchiya H; Kanazawa I

  Journal of the Neurological Sciences, 2001

  
• Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty

  Nagaoka N; Matsubara T; Okazaki K; Masuda N; Shikaura K; Hotta N

  JAPANESE HEART JOURNAL, Jan. 2001

  
• Detection of microsatellite alterations in nipple discharge accompanied by breast cancer

  Miyazaki, M.; Tamaki, Y.; Sakita, I.; Fujiwara, Y.; Kadota, M.; Masuda, N.; Ooka, M.; Ohnishi, T.; Ohue, M.; Sekimoto, M.; Tomita, N.; Furukawa, J.; Matsuura, N.; Monden, M.

  Breast Cancer Research and Treatment, 2000

  
• Identification of a 7-cM region of frequent allelic loss on chromosome band 16p13.3 that is specifically associated with anaplastic thyroid carcinoma

  Kadota, M.; Tamaki, Y.; Sakita, I.; Komoike, Y.; Miyazaki, M.; Ooka, M.; Masuda, N.; Fujiwara, Y.; Ohnishi, T.; Tomita, N.; Sekimoto, M.; Ohue, M.; Ikeda, T.; Kobayashi, T.; Horii, A.; Monden, M.

  Oncology Reports, 2000

  
• Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients

  Ooka, M.; Sakita, I.; Fujiwara, Y.; Tamaki, Y.; Yamamoto, H.; Aihara, T.; Miyazaki, M.; Kadota, M.; Masuda, N.; Sugita, Y.; Iwao, K.; Monden, M.

  Oncology Reports, 2000

  
• Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients

  Masuda, N.; Tamaki, Y.; Sakita, I.; Ooka, M.; Ohnishi, T.; Kadota, M.; Aritake, N.; Okubo, K.; Monden, M.

  Clinical Cancer Research, 2000

  
• Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

  Masuda, N.; Ohnishi, T.; Kawamoto, S.; Monden, M.; Okubo, K.

  Nucleic Acids Research, 1999

  
• Comparative Genomic Hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma

  Komoike, Y.; Tamaki, Y.; Sakita, I.; Tomita, N.; Ohue, M.; Sekimoto, M.; Miyazaki, M.; Kadota, M.; Masuda, N.; Ooka, M.; Ohnishi, T.; Nakano, Y.; Kozaki, T.; Kobayashi, T.; Matsuura, N.; Ikeda, T.; Horii, A.; Monden, M.

  International Journal of Oncology, 1999

  
• A case report: effective trans-arterial neoadjuvant chemotherapy with docetaxel for a local advanced breast cancer patient

  Sakita, I.; Tamaki, Y.; Miyazaki, M.; Kadota, M.; Masuda, N.; Ooka, M.; Ohue, M.; Sekimoto, M.; Tomita, N.; Monden, M.

  Gan to kagaku ryoho. Cancer & chemotherapy, 1999

  
• Early detection and prevention of cancers in various therapeutic areas. Discussion

  Akaza, H.; Tsuruo, T.; Tsukamoto, T.; Noguchi, S.; Moriwaki, H.; Isonishi, S.; Masuda, N.; Hinotsu, S.; Nash, A.F.; von Euler, M.; Wildin, J.; Stribling, D.

  Gan to kagaku ryoho. Cancer & chemotherapy, 1999

  
• Liver metastases from breast cancer--clinical features and treatment

  Masuda, N.; Yayoi, E.; Nakano, Y.; Monden, T.; Okamura, J.

  Gan to kagaku ryoho. Cancer & chemotherapy, 1998

  
• Analysis of 18 breast cancer patients with hypercalcemia

  Masuda, N.; Yayoi, E.; Furukawa, J.; Maruhashi, S.; Tokunaga, M.; Takiguchi, S.; Matsui, S.; Yano, H.; Tateishi, H.; Kinuta, M.; Maruyama, H.; Okamura, J.

  Gan to kagaku ryoho. Cancer & chemotherapy, 1998

  
• Appraisal of combination treatment for hepatocellular carcinoma: Long- term follow-up and Lipiodol-percutaneous ethanol injection therapy

  Tateishi, H.; Oi, H.; Masuda, N.; Yano, H.; Matsui, S.; Kinuta, M.; Maruyama, H.; Yayoi, E.; Okamura, J.

  Seminars in Oncology, 1997

  

Books and Other Publications

• 乳癌薬物療法の要点と盲点

  佐治 重衡; 増田 慎三; 戸井 雅和

  文光堂, 2023

  Find Kyoto University's collection of books :

  
• 治療戦略に役立つ臨床医・病理医のための乳腺病理の見かた・考え方

  増田 慎三; 堀井 理絵

  メジカルビュー社, 2022

  Find Kyoto University's collection of books :

  
• 治療戦略に役立つ : 臨床医・病理医のための乳腺病理の見かた・考え方

  増田 慎三; 堀井 理絵

  メジカルビュー社, 2022

  Find Kyoto University's collection of books :

  
• 乳がん薬物療法副作用マネジメント

  増田 慎三

  メジカルビュー社, 2021

  Find Kyoto University's collection of books :

  
• 乳がん薬物療法副作用マネジメント : プロのコツ

  増田 慎三

  メジカルビュー社, 2017

  Find Kyoto University's collection of books :

  
• Engineered cell manipulation for biomedical application

  明石 満; 赤木 隆美; 松崎 典弥; Zucolotto V

  Springer, 2014

  Find Kyoto University's collection of books :

  
• The periplasm

  Ehrmann Michael; American Society for Microbiology

  ASM Press, 2007

  Find Kyoto University's collection of books :

  

Awards

• 07 Jun. 2001

  日本乳癌学会研究奨励賞
• 13 Mar. 2003

  ガン研究助成奨励賞
• 12 Mar. 2002

  ガン研究助成奨励賞
• 09 Nov. 2018

  国立病院機構優秀論文賞最優秀賞

External funds: Kakenhi

• 日本人乳癌生存者における長期治療関連有害事象の包括的評価と個別化予防戦略の構築

  Grant-in-Aid for Scientific Research (C)

  Basic Section 53020:Cardiology-related

  Kyoto University

  加藤 恵理; 戸田恵理

  From 01 Apr. 2025, To 31 Mar. 2028, Granted

  腫瘍循環器;乳がん;サバイバー;PRO

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-25K11298/
• Study on stromal reaction and energy metabolism during breast cancer treatment

  Grant-in-Aid for Scientific Research (C)

  Kyorin University;Kyoto University

  TAKAYUKI UENO

  From 01 Apr. 2012, To 31 Mar. 2015, Project Closed

  乳癌;細胞死;エネルギー代謝;間質;科学内分泌療法;乳がん;化学内分泌療法;抗HER2療法

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24591900/

Education

Teaching subject(s)

• From 01 Apr. 2025, To 31 Mar. 2026

  Clinical Overview of Medicine F

  3228, Fall, Faculty of Medicine, 1
• From 01 Apr. 2025, To 31 Mar. 2026

  Gynecology and Obstetrics/Women Oncology

  C010, Fall, Faculty of Medicine, 1.5

Participation in PhD Defense

• Performance of dedicated breast PET in breast cancer screening:comparison with digital mammography plus digital breast tomosynthesis and ultrasound

  YUGE SHUNSUKE, Graduate School of Medicine, Sub-chief Examiner

  23 Jul. 2024

Administration

Faculty management (title, position)

• From 01 Nov. 2024, To 31 Oct. 2026

  期限付き教員審査委員会_委員
• From 01 Apr. 2025, To 31 Mar. 2027

  医学部医学科学務委員会_委員
• From 01 Apr. 2025, To 31 Mar. 2027

  医学図書館運営委員会_委員
• From 01 Apr. 2024, To 31 Mar. 2026

  クリニカルアナトミーラボ（ＣＡＬ）運営委員会_委員